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ABSTRACT 
 
NOVEL ROLES FOR THE TUMOR SUPPRESSOR APC THROUGH 
REGULATION OF GSK-3  
Alexander J. Valvezan 
Peter S. Klein 
 
Adenomatous Polyposis Coli (APC) is a tumor suppressor and essential negative 
regulator of the Wnt signaling pathway. Wnt signaling is crucial for proper 
patterning and cell fate specification during development and regulates stem cell 
homeostasis throughout adulthood. Mutations in Apc are strongly linked to 
human colorectal cancers and these mutations aberrantly activate Wnt signaling. 
How APC regulates the Wnt pathway and how oncogenic Apc mutations activate 
Wnt signaling and promote tumorigenesis are not fully understood. To address 
these questions, we utilized in vitro reconstitution assays, as well as Apc 
knockdown or mutation in human cells, zebrafish, and mice. We find APC directly 
enhances activity of Glycogen Synthase Kinase-3 (GSK-3), an essential 
regulator of diverse signaling pathways. Furthermore, APC loss of function 
mimics GSK-3 inhibition by reducing phosphorylation of Glycogen Synthase and 
by activating mechanistic Target of Rapamycin in Complex 1 (mTORC1). Thus 
we identify novel roles for APC as a regulator of GSK-3 activity and GSK-3 
dependent signaling. Wnts reduce GSK-3 activity through an unknown 
mechanism to activate downstream signaling. We find Wnts induce rapid APC 
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dissociation from the GSK-3/Axin complex, suggesting a new mechanism for how 
Wnts reduce GSK-3 activity. GSK-3 also regulates mTORC1, and we find 
oncogenic Apc mutations activate mTORC1. Furthermore, many Apc mutant 
phenotypes are partially rescued by mTORC1 inhibition, while others are rescued 
by combined mTORC1 and Wnt inhibition. These observations demonstrate roles 
for mTORC1 activation downstream of Apc mutation. Taken together, our 
findings provide new insight into APC function and the effects of oncogenic Apc 
mutation.  
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CHAPTER 1: INTRODUCTION 
 
1-1. APC is a tumor suppressor and essential negative regulator of the 
Wnt pathway 
 
Adenomatous Polyposis Coli (APC) is a large, multi-functional protein that 
plays critical roles in cell migration, apoptosis, cell cycle progression, axon 
outgrowth and guidance, cell-cell adhesion, regulation of microtubule dynamics, 
and many other important cellular processes (Hanson and Miller, 2005). APC is 
also an essential negative regulator of Wnt signaling, but how it performs this 
function is not well understood. Wnt signaling is essential during embryonic 
development for patterning, cell fate specification, and stem cell regulation. Wnt 
signals continue to influence stem cell fate decisions and tissue regeneration 
throughout adulthood (Clevers, 2006; MacDonald et al., 2009).  
Loss of function studies in model organisms demonstrate a requirement 
for APC in development and maintenance of many tissues and organs, often 
through its role in regulating Wnt signaling. In mice, homozygous Apc mutation 
results in lethality during gastrulation (Fodde et al., 1994). Tissue-specific Apc 
loss of function demonstrates essential roles for APC in development and 
maintenance of mouse liver (Decaens et al., 2008), mammary glands (Gallagher 
et al., 2002), intestine (Radulescu et al., 2010; Sansom et al., 2004), bone 
(Miclea et al., 2009), ocular lens (Martinez et al., 2009), and heart (Hasegawa et 
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al., 2002). Tissue-specific APC loss of function also causes nuclear β-catenin 
localization (a hallmark of active Wnt signaling) and activation of Wnt target 
genes in each of the respective tissues. In contrast to mice, Apc mutant zebrafish 
complete gastrulation due to the presence of maternal wild type APC. However, 
these fish also have many developmental defects and die a few days after 
fertilization (Hurlstone et al., 2003). These defects include unlooped hearts, 
hyperproliferation of endocardial cushions resulting in failure to form functional 
heart valves, reduced blood circulation, failure to form livers (or enlarged livers in 
heterozygous mutants), fin bud arrest, intestinal hyperproliferation, aberrant body 
curvature resulting from defects in morphogenesis of the anterior-posterior axis, 
failure to form inner ear structures and failure to form swim bladders (Goessling 
et al., 2008; Hurlstone et al., 2003). Nuclear β-catenin localization and 
upregulation of Wnt target genes are also observed in many tissues in Apc 
mutant zebrafish including the heart, eye, and liver (Goessling et al., 2008; 
Hurlstone et al., 2003; Stephens et al., 2010). In Drosophila, mutation of Apc2 
disrupts denticle patterning consistent with hyperactive Wingless (Wnt) signaling 
(McCartney et al., 1999). Mutation of Apc1 causes retinal photoreceptor 
apoptosis and pigment cell hypertrophy also as a result of hyperactive Wingless 
signaling (Ahmed et al., 1998). Combined loss of function of Apc1 and Apc2 
results in ubiquitous activation of Wingless signaling and lethality during larval 
stages (Ahmed et al., 2002). In C. Elegans, knockdown of apc-related-1 (apr-1) 
results in failure to form endoderm (Rocheleau et al., 1997). These data indicate 
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that APC is essential for the development of many organs and tissues.  
Mutations that aberrantly activate Wnt signaling, including mutations in 
Apc, are associated with human cancers (Anastas and Moon, 2012). APC 
functions as a tumor suppressor, and Apc mutations are strongly linked to 
colorectal cancer. Colorectal cancer is responsible for over 600,000 deaths 
worldwide each year, including 50,000 annually in the United States. It is the third 
most common cancer and second leading cause of cancer related death in the 
U.S. ( U.S. Cancer Statistics Working Group, 2013). Thus, better understanding 
of APC function and the consequences of oncogenic Apc mutation* is critical. 
Apc mutations are found in approximately 80 percent of sporadic 
colorectal cancers, and patients with germline Apc mutations develop Familial 
Adenomatous Polyposis (FAP), a condition marked by the formation of hundreds 
to thousands of intestinal adenomatous polyps. A small percent of these 
adenomas inevitably progress to invasive carcinomas and thus colonic resection 
is almost always required (Groden et al., 1991; Kinzler et al., 1991; Kinzler and 
Vogelstein, 1996; Miyoshi et al., 1992a). Mice and rats with germline Apc 
mutations also develop many intestinal adenomas. Homozygous Apc mutation 
results in early embryonic lethality. Therefore the human patients, mice, and rats 
that develop intestinal adenomas are heterozygous at the Apc locus in almost all 
cells. However, intestinal cells undergo loss of heterozygosity resulting in the  
 
*Throughout this dissertation “oncogenic Apc mutations” refer to truncating mutations within the 
mutation cluster region of Apc as described in section 1-3.  
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formation of tumors that are homozygous for the Apc mutation. Wnt signaling 
is aberrantly active in these tumors, consistent with the role of APC as a negative 
regulator of Wnt signaling (Amos-Landgraf et al., 2007; Kinzler and Vogelstein, 
1996; Su et al., 1992). Furthermore Wnt signaling promotes growth and 
maintenance of Apc mutant tumors (Foley et al., 2008; Roh et al., 2001; Scholer-
Dahirel et al., 2011).  
Interestingly, development of intestinal adenomas may begin prior to 
activation of Wnt signaling in some cases. Despite homozygous Apc mutation, 
nuclear β-catenin localization (a requirement for active Wnt signaling) and 
activation of Wnt target genes are not detected in all early adenomas in patients 
with FAP, microadenomas in a rat model of FAP, and sporadic human polyps 
(Amos-Landgraf et al., 2007; Anderson et al., 2002; Blaker et al., 2004; Caldwell 
et al., 2010; D'Orazio et al., 2002; Kobayashi et al., 2000).  
The importance of Wnt/β-catenin signaling downstream of Apc mutation is 
well established. However, the multitude of Wnt-independent APC functions, the 
prevalence of mutations in Apc compared to other Wnt pathway inhibitors in 
colorectal cancer, and the possibility of adenoma formation in the absence of 
active Wnt/β-catenin signaling led us to hypothesize that oncogenic Apc 
mutations may also function through additional mechanisms.  
 
1-2. The Wnt signaling pathway 
 
APC loss of function causes constitutive activation of the Wnt signaling 
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pathway, indicating APC is an essential negative regulator. Wnt signaling is 
crucial for establishing body axes and for patterning many tissues and organs 
during development, as well as regulating stem cell homeostasis and tissue 
maintenance in adults. Inhibition or ectopic activation of the pathway early on in 
development is lethal and later on can result in a wide variety of severe 
developmental defects. Improper regulation of the Wnt pathway is also implicated 
in human diseases including bipolar disorder and cancer. Mutations in Wnt 
pathway components that activate Wnt signaling have been identified in many 
cancers, including liver, prostate, breast, pancreatic, and most notably colorectal 
cancers, highlighting the importance of understanding Wnt signaling mechanisms 
(MacDonald et al., 2009).  
In unstimulated cells, APC, Glycogen Synthase Kinase-3 (GSK-3) and the 
transcriptional co-activator β-catenin bind directly to the scaffolding protein Axin 
in a cytoplasmic complex (Figure 1-1A). GSK-3 phosphorylates β-catenin within 
this complex, targeting β-catenin for ubiquitination and proteasome mediated 
degradation. APC also promotes β-catenin phosphorylation and degradation 
through an unknown mechanism. Wnt ligands bind to Frizzled receptors inducing 
formation of a complex with the essential co-receptor low density lipoprotein 
receptor-related protein 6 (LRP6) at the plasma membrane (Wehrli et al., 2000). 
LRP6 becomes phosphorylated which promotes direct interaction with Axin, thus 
recruiting the Axin complex to the membrane (Figure 1-1B). Subsequently, GSK-
3 is inhibited within the Axin complex through an unknown mechanism, allowing 
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Figure 1-1 
 
 
Figure 1-1. Wnt signaling inhibits GSK-3 within the Axin complex. (A) In 
unstimulated cells, GSK-3 phosphorylates and destabilizes β-catenin within the 
Axin complex. (B) Wnt signaling recruits Axin to phosphorylated LRP6, reducing 
GSK-3 activity and stabilizing β-catenin. We propose APC enhances GSK-3 
activity and Wnts induce APC dissociation from the Axin complex. 
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stabilization and accumulation of β-catenin. β-catenin then translocates into the 
nucleus and interacts with lymphocyte enhancer factor/T-cell factor (LEF/TCF) 
transcription factors to activate transcription of Wnt target genes (Clevers, 2006; 
MacDonald et al., 2009).  
Several hypotheses have been proposed to explain how Wnts stabilize β-
catenin. The E3 ubiquitin ligase β-TrCP interacts with the Axin complex to 
promote β-catenin ubiquitination and degradation, and β-TrCP dissociates from 
the complex following Wnt stimulation (Li et al., 2012). However, this event has 
not been observed until after β-catenin has accumulated. Similarly, Wnts induce 
Axin degradation and sequestration of GSK-3 inside multivesicular endosomes, 
but these events occur several hours after Wnt stimulation whereas GSK-3 is 
inhibited and β-catenin accumulates within minutes (Cook et al., 1996; Ding et 
al., 2000; Taelman et al., 2010). GSK-3 sequestration is also blocked by β-
catenin knockdown and induced by expression of stabilized β-catenin, 
suggesting GSK-3 sequestration occurs downstream of β-catenin stabilization 
during Wnt signaling. Therefore, while these events may contribute to long-term 
β-catenin stabilization, they do not explain initial β-catenin accumulation.   
 Alternatively, phosphorylated LRP6 may directly inhibit GSK-3 once the 
Axin complex is recruited to the Wnt/Frizzled/LRP6 complex at the membrane. 
The LRP6 intracellular domain, which contains the Wnt-dependent 
phosphorylation sites, reduces phosphorylation of GSK-3 substrates in in vitro 
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kinase assays for GSK-3 activity, and mutating the phosphorylation sites on 
LRP6 to alanines blocks this effect (Cselenyi et al., 2008; Piao et al., 2008; Wu et 
al., 2009). However, GSK-3 also phosphorylates the LRP6 intracellular domain, 
so reduced phosphorylation of other GSK-3 substrates used to assay GSK-3 
activity may be simply due to substrate competition. It is also noteworthy that 
micromolar concentrations of the LRP6 intracellular domain are required to 
reduce phosphorylation of other GSK-3 substrates in these reactions. Since Wnts 
induce recruitment of the Axin/GSK-3 complex to phosphorylated LRP6, further 
experiments are needed to determine whether pre-phosphorylated LRP6 can 
directly inhibit GSK-3.  
We propose an alternative hypothesis in which APC directly enhances 
GSK-3 activity and Wnts induce APC dissociation from the Axin complex to 
reduce GSK-3 activity and activate downstream signaling (Figure 1-1B). The 
rationale for this hypothesis will be discussed below.  
 
1-3. Direct APC interaction with Axin antagonizes Wnt signaling 
 
 Axin and APC interact directly through a regulator of G-protein signaling 
(RGS) domain within Axin and through three serine-alanine-methionine-proline 
(SAMP) repeats within APC (Behrens et al., 1998; Kishida et al., 1998). Axin and 
APC enhance β-catenin phosphorylation by GSK-3 in vitro, and adding them 
simultaneously enhances β-catenin phosphorylation even further. In the 
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presence of APC, an Axin mutant lacking the RGS domain (ΔRGS-Axin) reduces 
β-catenin phosphorylation by GSK-3 compared to wild type Axin (Hinoi et al., 
2000; von Kries et al., 2000). These data suggest that direct interaction between 
Axin and APC promotes β-catenin phosphorylation by GSK-3. In Xenopus 
embryos, ventral injection of ΔRGS-Axin but not wild type Axin causes axis 
duplication, indicating aberrant Wnt pathway activation (Hedgepeth et al., 1999; 
Sokol et al., 1991; Zeng et al., 1997). ΔRGS-Axin binds and sequesters GSK-3 in 
complexes that do not contain APC, suggesting direct Axin/APC interaction 
antagonizes Wnt signaling in vivo. ΔRGS-Axin also reduces phosphorylation of 
tau protein by GSK-3 in Xenopus oocytes, suggesting interaction with APC 
promotes GSK-3 activity towards multiple substrates (Hedgepeth et al., 1999).  
 Further evidence of the importance of Axin/APC interaction comes from 
mutations identified in cancers. Apc is mutated in approximately 80 percent of 
sporadic colorectal cancers, and hundreds of different mutations have been 
identified which cluster in a region that has been designated the Mutation Cluster 
Region (MCR). Almost all of these mutations result in expression of a truncated 
APC fragment that lacks the C-terminal half. Germline Apc mutations that cause 
Familial Adenomatous Polyposis are also truncating mutations located in the 
MCR (Hart et al., 1998; Kinzler and Vogelstein, 1996; Miyoshi et al., 1992b; 
Munemitsu et al., 1995; Nakamura et al., 1998). Interestingly, the remaining N-
terminal APC fragment is essential for colorectal cancer cell proliferation. 
Knocking down expression of this fragment reduces proliferation of colorectal 
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cancer cell lines and blocks tumor formation when cells from one of these lines 
are injected into nude mice (Chandra et al., 2012).   
Human APC protein contains 2843 amino acids and the MCR comprises 
amino acids approximately 1100 - 1500. The C-terminal end of the MCR is less 
than 100 amino acids N-terminal to the first SAMP repeat (Figure 1-2A). Thus the 
location of the MCR in relation to the SAMP repeats suggests truncating Apc 
mutations must remove the SAMP repeats and disrupt interaction with Axin to 
promote tumorigenesis. These truncating Apc mutations abolish direct Axin/APC 
interaction, resulting in reduced β-catenin phosphorylation by GSK-3 and thus 
reduced β-catenin ubiquitination and degradation which leads to β-catenin 
accumulation and constitutive activation of Wnt target genes. Wnt signaling is 
strongly activated in tumors resulting from truncating Apc mutation in humans, 
mice, rats, and zebrafish (Amos-Landgraf et al., 2007; Haramis et al., 2006; Hart 
et al., 1998; Miyoshi et al., 1992b; Munemitsu et al., 1995; Nakamura et al., 
1998). β-catenin knockdown reduces tumor cell proliferation and reduces the 
number of intestinal adenomas in Apc mutant mice (Foley et al., 2008). β-catenin 
knockdown also blocks growth of colorectal tumor xenografts harboring Apc 
mutations (Roh et al., 2001; Scholer-Dahirel et al., 2011). These data suggest 
aberrant Wnt pathway activation contributes to tumorigenesis downstream of Apc 
mutation.  
Importantly, reintroducing wild type APC into Apc mutant colorectal cancer 
cells or expressing fragments of APC that contain the SAMP repeats (SAMP  
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Figure 1-2 
 
Figure 1-2. Domain structure of APC and Axin. (A) The mutation cluster 
region (MCR) within APC is immediately N-terminal to the first Axin binding 
SAMP repeat. Oncogenic Apc mutations truncate within the MCR, removing the 
SAMP repeats and abolishing direct interaction with Axin. An example of a 
fragment containing the SAMP repeats (SAMP fragment) that rescues aberrant 
Wnt signaling in Apc mutant colorectal cancer cells is also shown. (B) Full length 
Axin binds APC, GSK-3 and β-catenin through distinct domains.  ΔRGS-Axin 
lacks the APC binding domain and therefore cannot directly interact with APC. 
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fragments, Figure 1-2A) rescues β-catenin phosphorylation by GSK-3, as well as 
β-catenin ubiquitination and degradation, and aberrant Wnt target gene activation 
(Kawahara et al., 2000; Yang et al., 2006). Deleting or mutating the SAMP 
repeats in APC blocks the rescue (Kawahara et al., 2000; von Kries et al., 2000). 
These data suggest that direct Axin/APC interaction is essential for promoting β-
catenin phosphorylation by GSK-3 to downregulate β-catenin and keep the Wnt 
pathway inactive. Mutations in the APC-binding domain of Axin have also been 
identified in colorectal cancers, medulloblastomas, hepatoblastomas, 
hepatocellular carcinomas, and prostate cancers (Salahshor and Woodgett, 
2005; Yardy et al., 2009; Zucman-Rossi et al., 2007). Taken together, these data 
led us to hypothesize that Wnts could regulate the Axin/APC interaction to 
stabilize β-catenin and activate downstream signaling.  
 
1-4. GSK-3 and Wnt signaling regulate mTORC1  
 
 Mechanistic Target of Rapamycin (mTOR) is an atypical serine/threonine 
kinase found in two distinct complexes termed mTOR Complex 1 (mTORC1) and 
mTOR Complex 2 (mTORC2). mTORC1 is a nutrient and energy sensor that 
integrates a variety of signals to regulate translation, energy metabolism, cell 
growth and proliferation, and cell survival decisions. mTORC1 is aberrantly active 
in human diseases including type 2 diabetes and many cancers (Laplante and 
Sabatini, 2012; Ma and Blenis, 2009; Zoncu et al., 2011). mTORC1 activation is 
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frequently observed in sporadic cancers and inherited polyposis syndromes 
including Tuberous Sclerosis Complex, Peutz-Jeghers syndrome, and the PTEN-
related hamartoma syndromes. These syndromes are caused by mutations in 
negative regulators of mTORC1 (Tsc1/Tsc2, Lkb1, and Pten respectively) (Inoki 
et al., 2005). The mTORC1 inhibitor Everolimus was recently approved by the 
U.S. Food and Drug Administration for treatment of Tuberous Sclerosis Complex 
(Laplante and Sabatini, 2012), highlighting the importance of mTORC1 
activation.  
 mTORC1 activity is regulated by many upstream factors including the 
TSC1-TSC2-TBC1D7 complex. Tuberous Sclerosis Complex 2 (TSC2) is a 
GTPase activating protein for the small GTPase Rheb which activates mTORC1. 
Thus TSC2 negatively regulates mTORC1 (Dibble et al., 2012; Inoki et al., 2003; 
Tee et al., 2003). Active mTORC1 directly phosphorylates several downstream 
effectors, including S6 kinase 1 which is activated by phosphorylation and in turn 
phosphorylates the ribosomal protein S6 to promote translation (Ma and Blenis, 
2009).  
TSC2 is also regulated by multiple upstream factors including ERK, Akt, 
AMPK, and GSK-3. GSK-3 directly phosphorylates and activates TSC2 and 
therefore GSK-3 also negatively regulates mTORC1 (Figure 1-3A). GSK-3 
knockdown or inhibition activates mTORC1, indicating GSK-3 is essential for 
keeping mTORC1 inactive (Huang et al., 2009; Inoki et al., 2006). TSC2 can 
physically associate with the Axin complex, and Axin knockdown also  
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Figure 1-3 
 
Figure 1-3. GSK-3 negatively regulates mTORC1. (A) TSC2 negatively 
regulates mTORC1 and GSK-3 phosphorylates and activates TSC2. Thus GSK-3 
also negatively regulates mTORC1. mTORC1 activation promotes S6 
phosphorylation. (B) TSC2 can associate with the Axin complex. Wnt signaling 
and Axin knockdown activate mTORC1.  
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activates mTORC1 (Inoki et al., 2006; Mak et al., 2005). Furthermore, Wnt 
ligands inhibit GSK-3 in the Axin complex, reduce TSC2 phosphorylation, and 
activate mTORC1. These data suggest mTORC1 is regulated by Wnts and GSK-
3 in the Axin complex. mTORC1 activation by Wnts occurs within minutes, 
correlating with GSK-3 inhibition (Cook et al., 1996; Inoki et al., 2006). Regulation 
of mTORC1 by Wnts is independent of β-catenin as β-catenin knockout or 
overexpression does not affect mTORC1 activation (Inoki et al., 2006). The role 
of Wnt signaling, GSK-3, and Axin in regulating mTORC1 led us to hypothesize 
that APC negatively regulates mTORC1 and also led us to ask whether 
oncogenic APC mutations activate mTORC1. 
 
1-5. GSK-3 is an essential regulator of diverse signaling pathways 
 
  GSK-3 inhibits Wnt signaling by directly phosphorylating and destabilizing 
β-catenin, and inhibits mTORC1 by directly phosphorylating and activating TSC2. 
GSK-3 also phosphorylates over 100 other putative substrates including p53, tau, 
amyloid precursor protein (APP), c-Myc, BCL-3, Cyclin D1, Cyclin E, Hypoxia-
inducible factor-1 (HIF-1), and c/EBPβ. Through phosphorylation of its 
substrates, GSK-3 regulates many signaling pathways including ERK, Notch, 
Sonic Hedgehog, Bone Morphogenetic Protein (BMP), and Insulin/growth factor 
signaling through PI3K and Akt (Kaidanovich-Beilin and Woodgett, 2011; Kim 
and Snider, 2011; Kockeritz et al., 2006). For example, GSK-3 phosphorylates 
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and destabilizes the Notch signaling effector Notch intracellular domain (NICD). 
Inhibition or deletion of GSK-3 increases NICD levels and activates Notch target 
genes (Jin et al., 2009; Kim et al., 2009). Similarly, GSK-3 phosphorylates the 
Sonic Hedgehog pathway effector Ci/Gli, promoting proteolytic processing of 
Ci/Gli to generate a truncated repressor. GSK-3 loss of function causes 
accumulation of full length Ci/Gli and activates Sonic Hedgehog target genes 
(Forde and Dale, 2007; Jia et al., 2002; Price and Kalderon, 2002).  
 GSK-3 is a constitutively active and ubiquitously expressed 
serine/threonine kinase encoded by two separate genes: Gsk-3α and Gsk-3β. 
The kinase domains of GSK-3α and GSK-3β are 98 percent identical, and the 
two isoforms function redundantly in the Wnt pathway (Doble et al., 2007; Doble 
and Woodgett, 2003). GSK-3 autophosphorylates at a tyrosine residue within its 
activation loop during its chaperone-mediated folding and maturation. This 
phosphorylation enhances serine/threonine kinase activity of the mature GSK-3 
(Cole et al., 2004; Lochhead et al., 2006). GSK-3 can also be inhibited by 
phosphorylation at an N-terminal serine residue (serine 21 on GSK-3α and serine 
9 on GSK-3β), which creates a competitive pseudosubstrate inhibition motif 
(Dajani et al., 2001).  
Upstream signals in general inhibit GSK-3 to activate downstream 
signaling. Insulin and other growth factors activate phosphatidylinositol-3-kinase 
(PI3K) which phosphorylates and activates Akt. Akt in turn phosphorylates GSK-
3 on serine 9/21, thus inhibiting GSK-3 and allowing activation of downstream 
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effectors such as Glycogen Synthase, the eponymous substrate for GSK-3 
(Cross et al., 1995; McManus et al., 2005; Proud, 2006). Importantly, neither 
Wnts nor Insulin/Akt induce serine 9/21 phosphorylation of GSK-3 in the Axin 
complex, and Wnt signaling is unaffected by mutation of serine 9/21 to alanine 
(Ding et al., 2000; McManus et al., 2005; Ng et al., 2009). These data suggest 
Wnts inhibit GSK-3 by a mechanism other than serine 9/21 phosphorylation, and 
that Wnt-regulated and Insulin/Akt-regulated GSK-3 represent two distinct 
subcellular pools. 
Misregulation of GSK-3 activity is implicated in human diseases including 
bipolar disorder, schizophrenia, and Alzheimer’s Disease. The GSK-3 inhibitor 
lithium has been used to treat bipolar disorder for over 50 years, and GSK-3 has 
been shown to be the relevant target of lithium in regulating mammalian 
behaviors, suggesting misregulation of GSK-3 contributes to bipolar disorder 
(Valvezan and Klein, 2011). Mutations in the disrupted in schizophrenia 1 (Disc1) 
gene have been linked to schizophrenia, and DISC1 is an endogenous GSK-3 
inhibitor, suggesting misregulation of GSK-3 may contribute to schizophrenia as 
well (Mao et al., 2009; Millar et al., 2000; Valvezan and Klein, 2011). Two major 
pathological hallmarks of Alzheimer’s disease are aggregates of insoluble 
amyloid beta peptide (amyloid plaques) and neurofibrillary tangles composed 
mainly of the GSK-3 substrate tau hyperphosphorylated at the GSK-3 
phosphorylation sites. GSK-3 promotes processing of the amyloid precursor 
protein (APP) to generate amyloid beta peptide. GSK-3 inhibition or loss of 
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function reduces amyloid plaque and neurofibrillary tangle formation and 
improves cognitive function in mouse models of Alzheimer’s disease (Hernandez 
et al., 2009; Hurtado et al., 2012; Phiel et al., 2003). Thus GSK-3 is an essential 
regulator of many substrates and signaling pathways, and improper regulation of 
GSK-3 is implicated in human diseases, highlighting the importance of 
understanding how GSK-3 activity is regulated.   
 
1-6. Parallels in APC and GSK-3 function 
  
 Interestingly, APC and GSK-3 are involved in many of the same 
developmental and cellular processes, and their gain and loss of function 
phenotypes are often similar. For example, knockdown of apc-related-1 (apr-1) in 
C. Elegans results in ectopic pharyngeal tissue and failure to form endoderm 
(Rocheleau et al., 1997), and these phenotypes are also observed when gsk-3 is 
knocked down (Schlesinger et al., 1999). Loss of function mutations in 
Drosophila Gsk-3β (zw-3) phenocopy a hypomorphic APC2 mutation which 
disrupts localization of nuclei to the cortex of syncytial Drosophila embryos 
(McCartney et al., 2001). Zw-3 knockdown also disrupts denticle patterning and 
causes anterior gut expansion, like APC2 knockdown (Yu et al., 1999). Deletion 
of Apc or Gsk-3 in mouse intestine blocks cell cycle arrest in response to mitotic 
spindle disruption, indicating APC and GSK-3 contribute to the mitotic spindle 
assembly checkpoint (Radulescu et al., 2010). GSK-3 knockdown in mouse bone 
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marrow causes short term expansion and long term depletion of hematopoietic 
stem cells (HSCs) (Huang et al., 2009). Similarly, conditional APC deletion in 
mouse bone marrow causes short term expansion and long term HSC depletion 
(Qian et al., 2008). APC and GSK-3 are both essential for spindle formation 
during mitosis. GSK-3 localizes to centrosomes and spindle microtubules, and 
GSK-3 inhibitors disrupt spindle orientation, resulting in chromosomal 
misalignment (Wakefield et al., 2003). APC also localizes to centrosomes and 
spindle microtubules and APC loss of function disrupts spindle orientation and 
causes chromosome misalignment (Caldwell and Kaplan, 2009; Hanson and 
Miller, 2005; Lui et al., 2011). GSK-3 phosphorylates Histone H1.5 to regulate 
chromatin condensation during mitosis, and APC is required for compaction of 
mitotic chromatin (Dikovskaya et al., 2012; Happel et al., 2009).  
 APC and GSK-3 also play similar roles in neurite outgrowth and the 
establishment of axonal-dendritic polarity. Immature neurons extend several 
small neurites, one of which is selected to become the mature axon. The Par 
complex including mammalian partition defective 3 (mPar3), which is essential 
for polarization of many cell types, accumulates at the tip of the neurite which will 
become the mature axon. mPar3 and the Par complex are essential for axon 
specification and establishment of neuronal polarity (Chen et al., 2013). APC is 
required for mPar3 localization and axon specification. Furthermore, APC 
overexpression results in mPar3 localization in two or more neurites which grow 
and express axonal markers, suggesting APC promotes mPar3 accumulation at 
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neurite tips and axon specification. Similarly, GSK-3 inhibitors block mPar3 
accumulation and neurite outgrowth (Shi et al., 2004). Taken together, these data 
suggest APC and GSK-3 have many similar functions and led us to hypothesize 
that APC and GSK-3 functionally interact in Wnt-independent settings. 
 
1-7. Research summary 
 
 Wnt signaling is essential for patterning during embryonic development, 
stem cell fate decisions in adults, and progression of many cancers. The 
functions of key players in the Wnt pathway, and the mechanisms controlling key 
steps in Wnt signal transduction are not understood. APC inhibits Wnt signaling 
by promoting phosphorylation and degradation of β-catenin. Wnts stabilize β-
catenin by reducing its phosphorylation. How APC and Wnts regulate β-catenin 
phosphorylation is unknown. To investigate the role of APC in regulation of β-
catenin, we tested a role for APC in regulating GSK-3 activity. We tested this in in 
vitro kinase assays for GSK-3 activity and by knocking down APC in human cells. 
We find that APC directly enhances GSK-3 activity, and thus promotes 
phosphorylation of β-catenin and other substrates by GSK-3. Interestingly, we 
also identify new roles for APC as a negative regulator of Glycogen Synthase 
and mTORC1, like GSK-3. Furthermore, we find Wnt signaling induces APC 
dissociation from the Axin/GSK-3 complex, suggesting a novel mechanism for 
how Wnts inhibit GSK-3. These data suggest APC promotes β-catenin 
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phosphorylation by enhancing GSK-3 activity, and that Wnts reduce GSK-3 
activity and β-catenin phosphorylation by causing APC to dissociate from Axin. 
These data are presented in Chapter 2 as published in Valvezan et al. (Journal of 
Biological Chemistry, 2012).  
 Truncating Apc mutations are strongly linked to colorectal cancers. 
Therefore it is essential to identify signaling mechanisms that act downstream to 
mediate the effects of Apc mutation. Constitutive activation of Wnt/β-catenin 
signaling is widely accepted as the predominant mechanism responsible for Apc 
mutant phenotypes. APC negatively regulates mTORC1 and mTORC1 activation 
promotes development and progression of many cancers. We hypothesized that 
truncating Apc mutations activate mTORC1 which also contributes to resulting 
phenotypes. We tested this hypothesis in Apc mutant zebrafish and mice. We 
found mTORC1 is strongly activated in many tissues in Apc mutant zebrafish and 
in intestinal polyps in Apc mutant mice. mTORC1 inhibition rescues several Apc 
mutant phenotypes, and combined mTORC1 and Wnt inhibition rescues 
additional phenotypes. These data indicate a role for mTORC1 downstream of 
truncating Apc mutation, and are presented in Chapter 3.  
 Taken together, our findings identify novel roles for APC in the Wnt 
pathway and other GSK-3 dependent signaling pathways. Our work also 
establishes mTORC1 as a critical effector downstream of oncogenic Apc 
mutations. Conclusions, implications, and future directions will be discussed in 
Chapter 4. 	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CHAPTER 2: ADENOMATOUS POLYPOSIS COLI (APC) REGULATES 
MULTIPLE SIGNALING PATHWAYS BY ENHANCING GLYCOGEN 
SYNTHASE KINASE-3 (GSK-3) ACTIVITY 
 
2-1. Summary 
 
Glycogen synthase kinase-3 (GSK-3) is essential for many signaling pathways 
and cellular processes. As Adenomatous Polyposis Coli (APC) functions in many 
of the same processes, we investigated a role for APC in the regulation of GSK-
3-dependent signaling. We find that APC directly enhances GSK-3 activity. 
Furthermore, knockdown of APC mimics inhibition of GSK-3 by reducing 
phosphorylation of glycogen synthase and by activating mTOR, revealing novel 
roles for APC in the regulation of these enzymes. Wnt signaling inhibits GSK-3 
through an unknown mechanism, and this results in both stabilization of β-
catenin and activation of mTOR. We therefore hypothesized that Wnts may 
regulate GSK-3 by disrupting the interaction between APC and the Axin-GSK-3 
complex. We find that Wnts rapidly induce APC dissociation from Axin, 
correlating with β-catenin stabilization. Furthermore, Axin interaction with the Wnt 
co-receptor LRP6 causes APC dissociation from Axin. We propose that APC 
regulates multiple signaling pathways by enhancing GSK-3 activity, and that  
 
*The text and figures in Chapter 2 are presented as published in Valvezan et al. Adenomatous 
Polyposis Coli (APC) Regulates Multiple Signaling Pathways by Enhancing Glycogen Synthase 
Kinase-3 (GSK-3) Activity. The Journal of Biological Chemistry. Vol. 287, No. 6, pp. 3823–3832, 
February 3, 2012. Experiments in Supplemental Figure S2-7 were performed by co-author Fang 
Zhang. 
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Wnts induce APC dissociation from Axin to reduce GSK-3 activity and activate 
downstream signaling. APC regulation of GSK-3 also provides a novel 
mechanism for Wnt regulation of multiple downstream effectors, including β -
catenin and mTOR. 
 
2-2. Introduction  
 
 Glycogen Synthase Kinase-3 (GSK-3) plays critical roles in a wide variety 
of essential biological processes during development and throughout adulthood, 
including tissue patterning, glucose metabolism, apoptosis, stem cell 
homeostasis and cell cycle regulation (Kockeritz et al., 2006). GSK-3 has over 40 
known direct substrates, and regulates many signaling pathways including the 
Wnt, MAPK/ERK, BMP, mTOR, and Insulin pathways (Fuentealba et al., 2007; 
Fukuda et al.; Inoki et al., 2006; Kockeritz et al., 2006; Wang et al., 2006). 
Misregulation of GSK-3 has been proposed to play important roles in human 
disorders such as bipolar disorder, schizophrenia, Alzheimer’s disease, and 
cancer (Hernandez et al., 2009; Jope and Roh, 2006; Luo, 2009). Therefore 
understanding the mechanisms that control GSK-3 activity is essential to 
understanding many biological processes as well as human disorders.  
 GSK-3 is a constitutively active kinase that typically inhibits downstream 
signaling events; thus extracellular signals in general inhibit GSK-3 to induce 
intracellular signaling events. For example, Insulin promotes N-terminal 
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phosphorylation of GSK-3 (Ser9/21), creating a pseudosubstrate motif that 
inhibits GSK-3 and allows activation of Glycogen Synthase (Cross et al., 1995; 
Dajani et al., 2001; McManus et al., 2005). Wnt signaling also inhibits GSK-3 
activity, but through a mechanism that is independent of ser9/21 phosphorylation 
(Cook et al., 1996; Ding et al., 2000; McManus et al., 2005). The mechanism of 
GSK-3 inhibition by Wnts remains poorly understood.   
The Wnt signaling pathway is essential for patterning and cell fate 
specification during embryonic development, and plays critical roles in stem cell 
homeostasis and tissue regeneration throughout adulthood (Clevers, 2006; 
MacDonald et al., 2009). Ectopic activation of the Wnt pathway causes many 
human cancers, including breast, prostate, liver, and most notably colorectal 
cancers (Paul and Dey, 2008; Salahshor and Woodgett, 2005). In the absence of 
Wnt ligands, GSK-3, the transcription factor β-catenin, and the tumor suppressor 
Adenomatous Polyposis Coli (APC) bind directly to the scaffolding protein Axin in 
a robust complex (Peterson-Nedry et al., 2008) that facilitates destabilizing 
phosphorylation of β-catenin by GSK-3. Canonical Wnt ligands bind to their 
receptor Frizzled and induce phosphorylation of the co-receptor LRP5/6, 
promoting direct interaction between LRP6 and Axin. This reduces GSK-3 
activity, allowing stabilization of ß-catenin which then enters the nucleus to 
activate transcription (Clevers, 2006; MacDonald et al., 2009). Several 
mechanisms have been proposed to explain Wnt-induced inhibition of GSK-3, 
including Axin degradation (Lee et al., 2003; Tolwinski et al., 2003) and 
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sequestration of GSK-3 within multivesicular endosomes (Taelman et al., 2010). 
However, these events occur several hours after stimulation, whereas reduced 
GSK-3 activity and β-catenin stabilization are detected within minutes (Cook et 
al., 1996; Ding et al., 2000). In addition, the LRP6 intracellular domain can 
directly inhibit GSK-3, suggesting an alternative and plausible mechanism for 
inhibition of GSK-3 once it is recruited to the receptor/co-receptor complex 
(Cselenyi et al., 2008; Piao et al., 2008; Wu et al., 2009). However, micromolar 
concentrations of the LRP6 intracellular domain peptide are required to inhibit 
GSK-3, and the peptide itself is a GSK-3 substrate and thus may simply compete 
with the substrates that were assayed for phosphorylation by GSK-3.   
Similar to GSK-3, APC also negatively regulates the Wnt pathway by 
promoting β-catenin phosphorylation and degradation (Hinoi et al., 2000; Su et 
al., 2008; Yang et al., 2006). APC interaction with Axin requires Ser-Ala-Met-Pro 
(SAMP) repeats on APC (Behrens et al., 1998). Mutations in Apc that delete the 
SAMP repeats and eliminate Axin binding are strongly linked to colorectal 
cancers, and cause constitutively elevated β-catenin levels and constitutive 
activation of Wnt target genes (Munemitsu et al., 1995).  These effects can be 
rescued by reintroduction of wild type APC or fragments of APC that bind Axin 
through SAMP repeats, but not by SAMP mutant fragments that do not bind Axin 
(Kawahara et al., 2000; Munemitsu et al., 1995; von Kries et al., 2000).  
Therefore APC interaction with Axin is critical for downregulating β-catenin and 
maintaining the Wnt pathway in an inactive state, and thus parallels the function 
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of GSK-3 in Wnt signaling. 
In addition to their parallel roles in Wnt signaling, APC and GSK-3 have 
similar functions in processes such as cell cycle regulation and apoptosis (Forde 
and Dale, 2007; Hanson and Miller, 2005).  For example, APC and GSK-3 are 
both required for proper spindle formation during mitosis (Caldwell and Kaplan, 
2009; Hanson and Miller, 2005; Wakefield et al., 2003).  As APC promotes 
phosphorylation of β-catenin, a direct GSK-3 substrate, and is involved in many 
of the same processes as GSK-3, we hypothesized that APC regulates additional 
GSK-3 substrates and GSK-3 dependent signaling pathways.  We find that APC 
directly regulates GSK-3 activity. Thus APC promotes phosphorylation of the 
direct GSK-3 substrate Glycogen Synthase independently of Wnt signaling. We 
also find that APC is required for GSK-3-dependent negative regulation of 
mTOR.  This led us to hypothesize that a key function of APC in the Axin 
complex is to enhance GSK-3 activity and that Wnts reduce GSK-3 activity by 
causing dissociation of APC from the Axin complex. In support of this hypothesis, 
we find that Wnts rapidly disrupt the endogenous APC-Axin interaction.  We 
propose that APC regulates multiple signaling pathways by enhancing GSK-3 
activity, and that Wnts cause APC to dissociate from the Axin complex in order to 
reduce GSK-3 activity and activate downstream signaling. 
 
2-3. Results 
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2-3-1. APC regulates Glycogen Synthase through GSK-3 
 
APC promotes phosphorylation of the direct GSK-3 substrate β-catenin, 
and APC and GSK-3 function in many of the same cellular processes (Hanson 
and Miller, 2005; Kockeritz et al., 2006); we therefore asked whether APC 
promotes phosphorylation of additional GSK-3 substrates. Glycogen Synthase 
(GS), the eponymous substrate for GSK-3, is expressed in 293T cells and is 
constitutively phosphorylated by GSK-3 to inhibit its activity. Knocking down APC 
with siRNA reduced site-specific phosphorylation of GS, similar to treating with 
the GSK-3 inhibitor LiCl (Figure 2-1A) or alternative small molecule GSK-3 
inhibitors (Supplemental Figure S2-1).  These results were confirmed using an 
additional non-overlapping APC siRNA (Supplemental Figure S2-2).  Insulin and 
other growth factors reduce GS phosphorylation through phosphorylation of Akt 
and GSK-3 (Alessi et al., 1996; Cross et al., 1995; McManus et al., 2005). 
Interestingly, knocking down APC did not affect phosphorylation of Akt or GSK-3, 
indicating APC does not regulate GS by activating Insulin signaling upstream of 
GSK-3 (Figure 2-1A).  GS phosphorylation was rescued after APC knockdown by 
expressing a large fragment of APC (SAMP fragment) that also rescues β-
catenin levels in colorectal carcinoma cells that lack wild type APC (Figure 2-1B).  
Importantly, LiCl blocked the rescue of GS phosphorylation by APC-SAMP, 
showing that the rescue is dependent on GSK-3 activity (Figure 2-1B). Knocking 
down APC in these cells also activated Wnt signaling, as assessed by activity of  
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Figure 2-1 
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Figure 2-1. APC regulates Glycogen Synthase through GSK-3.  (A) APC was 
knocked down by siRNA in 293T cells and phosphorylation of Glycogen 
Synthase (GS) at an established GSK-3 target site (GS-Ser641) was assessed 
by immunoblotting with a phospho-specific antibody. The same samples were 
immunoblotted for total GS (loading control), phospho-Akt (Ser473), phospho-
GSK-3 (Ser9/21), and APC. Cells in lane 2 were also treated with15mM LiCl. 
Cells were also transfected with a scrambled siRNA (control). APC knockdown 
reduced APC protein levels and endogenous GS phosphorylation without 
affecting total GS or phosphorylation of Akt or GSK-3.  (B) To rescue GS 
phosphorylation in APC knockdown cells, the myc-tagged SAMP fragment of 
APC was co-transfected with scrambled (control) or APC siRNAs. “EV” indicates 
empty vector control. The SAMP fragment of APC rescues phosphorylation of 
GS in APC knockdowns, and this rescue is blocked by LiCl.   
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a β-catenin responsive reporter (Supplemental Figure S2-3A), consistent with the 
known role for APC as a negative regulator of the Wnt pathway (Clevers, 2006; 
MacDonald et al., 2009). To rule out the possibility that GS phosphorylation was 
indirectly regulated by Wnt signaling downstream of the APC/Axin degradation 
complex, we expressed a stabilized and hence constitutively active form of β-
catenin. Although stabilized β-catenin potently activated the Wnt reporter, it had 
no effect on phospho-GS (Supplemental Figure S2-3B), demonstrating that the 
reduction in GS phosphorylation in response to APC knockdown is not due to 
downstream activation of the Wnt pathway. These results suggest a novel role 
for APC in the regulation of GSK-3 activity. 
We also asked whether APC knockdown affects GS regulation by insulin. 
We generated an HEK293 cell line that stably expresses an siRNA targeting APC 
(Schneikert and Behrens, 2006). Stable knockdown of APC reduces GS 
phosphorylation (Supplemental Figure S2-4), similar to Figure 2-1. Insulin also 
reduces GS phosphorylation in the parental HEK293 line (Alessi et al., 1996), but 
combined APC knockdown and insulin treatment do not further reduce GS 
phosphorylation (Supplemental Figure S2-4). Insulin did not induce 
phosphorylation of GSK-3 stably associated with the endogenous APC/Axin 
complex (Supplemental Figure S2-5), consistent with previous observations that 
the Axin-associated/Wnt-regulated subcellular pool of GSK-3 is distinct from 
insulin-regulated GSK-3 (Ding et al., 2000; McManus et al., 2005). Stable 
association of APC and GSK-3 independent of the Axin complex has not been 
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demonstrated to our knowledge.  
 
2-3-2. APC regulates mTOR through GSK-3 
 
GSK-3 negatively regulates mammalian Target of Rapamycin (mTOR), 
and either pharmacological or genetic inhibition of GSK-3 activates mTOR in vivo 
(Huang et al., 2009; Inoki et al., 2006).  If APC promotes phosphorylation of other 
substrates by GSK-3, in addition to GS and β-catenin, then knockdown of APC 
may also activate mTOR. In support of this, knockdown of APC activated mTOR, 
as assessed by increased phosphorylation of ribosomal protein S6, similar to 
inhibiting GSK-3 with LiCl (Figure 2-2A), other small molecule GSK-3 inhibitors 
(Supplemental Figure S2-1), or knocking down Gsk3 expression (Huang et al., 
2009; Inoki et al., 2006). This was also confirmed using a non-overlapping APC 
siRNA (Supplemental Figure S2-2), and rescued by expressing the SAMP 
fragment of APC. This rescue was also blocked by LiCl (Figure 2-2B). The effect 
of APC knockdown on S6 phosphorylation was blocked by the mTOR inhibitor 
rapamycin (Figure 2-2D), further supporting our conclusion that APC functions 
upstream of mTOR.  As above, expression of stabilized β-catenin had no effect 
on S6 phosphorylation (Supplemental Figure S2-3), indicating that mTOR 
activation resulting from APC knockdown is not due to activation of Wnt signaling 
downstream of ß-catenin. 
Wnts regulate the GSK-3/APC/Axin complex to inhibit GSK-3 and activate  
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Figure 2-2 
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Figure 2-2. APC regulates mTOR through GSK-3.  (A) APC was knocked 
down by siRNA, as in Figure 2-1, and mTOR activity was assessed as 
phosphorylation of ribosomal protein S6 (Ser235/236, upper panel). Inhibition of 
GSK-3 with LiCl also activated mTOR. Total S6 (middle panel) is shown as a 
loading control. The cell lysates in panels A and B are the same as those used in 
Figure 2-1. (B) APC knockdown increased S6 phosphorylation and this effect 
was rescued by the SAMP fragment of APC. (C) Expression of full length APC 
reduces S6 phosphorylation in SW480 colorectal carcinoma cells, which only 
express a truncated APC that lacks the SAMP repeats. Transfection efficiency 
was estimated at 30% based on expression of YFP (data not shown). LiCl 
increased S6 phosphorylation in cells expressing wild type APC.  (D) Rapamycin 
(10nM) blocks S6 phosphorylation after APC knockdown.   
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β-catenin and mTOR (Inoki et al., 2006; MacDonald et al., 2009). As APC 
promotes Glycogen Synthase phosphorylation by GSK-3, we asked whether 
Wnts affect Glycogen Synthase phosphorylation. L cells were treated with control 
or Wnt3a conditioned medium for up to two hours, but no change in GS 
phosphorylation was detected (Supplemental Figure S2-6A). Furthermore, Axin 
knockdown activates mTOR as observed previously (Inoki et al., 2006), but does 
not affect GS phosphorylation (Supplemental Figure S2-6B). Taken together, 
these data suggest Wnts and Axin regulate mTOR but not GS. 
The SW480 human colorectal carcinoma cell line lacks wild-type APC, 
and instead expresses a truncated APC that fails to interact with Axin or to 
downregulate β-catenin (Kishida et al., 1998; Munemitsu et al., 1995).  
Phosphorylation and degradation of β-catenin can be restored in these cells by 
reintroduction of wild type APC (or the SAMP fragment) (Hinoi et al., 2000; 
Munemitsu et al., 1995; Su et al., 2008; Yang et al., 2006). Interestingly, S6 
phosphorylation readily detected in untreated SW480 cells was not further 
increased by LiCl, in contrast to the effects observed in 293T cells, which 
express wild type APC (Figure 2-2C, compare lanes 1,3). We hypothesized that 
mTOR is aberrantly active in these cells due to the truncating APC mutations.  
Consistent with this idea, reintroduction of wild type APC reduces S6 
phosphorylation, suggesting a novel role for APC as a negative regulator of 
mTOR. Furthermore, when wild-type APC was introduced into SW480 cells, LiCl 
activated mTOR (Figure 2-2C, compare lanes 2,4), indicating that restoring wild-
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type APC restores GSK-3 activity and mTOR sensitivity to LiCl.  Restoring wild 
type APC in SW480 cells did not affect Akt or GSK-3 phosphorylation. These 
data support a signaling pathway in which APC, acting through GSK-3, 
suppresses mTOR activity.  
 
2-3-3. APC directly enhances GSK-3 activity.  
 
 Knocking down APC reduced phosphorylation of GS, a direct GSK-3 
substrate, without affecting known signaling mechanisms upstream of GSK-3. To 
test whether APC regulates GSK-3 activity directly, we performed in vitro kinase 
reactions using purified recombinant proteins. Surprisingly, addition of the SAMP 
fragment of APC increases GSK-3-dependent phosphorylation of both Tau 
protein (Figure 2-3A lanes 2,3) and β-catenin (Figure 2-3B lanes 3,4) by 
approximately 5-7 fold. GSK-3 dependent phosphorylation of ß-catenin normally 
occurs within the Axin complex, and requires a priming phosphorylation of ß-
catenin by Casein Kinase I alpha (CKIα) (Liu et al., 2002). Thus, we added Axin 
and Casein Kinase I (CKI) to the in vitro kinase reaction and again observed that 
SAMP further enhanced β-catenin phosphorylation by GSK-3. Thus, APC directly 
enhances GSK-3 activity towards multiple substrates both in the presence and 
absence of the Axin complex.  
We also asked whether restoring wild type APC in APC-deficient 
colorectal carcinoma cells could enhance GSK-3 activity. We used an inducible  
	   36 
 
Figure 2-3 
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Figure 2-3. APC directly enhances GSK-3 activity. In vitro kinase reactions 
were carried out using purified recombinant proteins. (A) Addition of the SAMP 
fragment (80nM) of APC, but not BSA, directly enhances Tau phosphorylation 
(Ser 396/404) by GSK-3 by approximately 5 fold. For image quantification, 
phospho-Tau was normalized to total Tau and then all lanes were normalized to 
Lane 2. (B) SAMP, but not BSA, directly enhances β-catenin phosphorylation 
(Ser33/37/41) by GSK-3 by approximately 7 fold. For image quantification, 
phospho-β-catenin was normalized to total β-catenin and then all lanes were 
normalized to Lane 3. (C) SAMP enhances β-catenin phosphorylation by GSK-3 
in the presence of Axin and Casein Kinase I (CKI) by approximately 2 fold. For 
image quantification, phospho-β-catenin was normalized to total β-catenin and 
then Lane 2 was normalized to Lane 1.  
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APC cell line derived from HT29 cells, human colorectal carcinoma cells that 
express a truncated APC similar to SW480 cells (Morin, 1999). HT29-APC cells 
express full length APC under control of the zinc-inducible metallothionein 
promoter and control HT29-ß-gal cells express ß-galactosidase (Supplemental 
Figure S2-7C). We immunoprecipitated endogenous GSK-3 from untreated or 
zinc treated cells and measured phosphorylation of a peptide derived from 
Glycogen Synthase (GS-2) by incorporation of 32P (Supplemental Figure S2-7). 
APC induction enhances GS-2 phosphorylation, whereas zinc treatment in HT29-
ß-gal cells has no effect. The GSK-3 inhibitor SB216763 blocks GS-2 
phosphorylation in all groups indicating that GS-2 is phosphorylated primarily by 
GSK-3 in this assay. These data confirm that wild type APC enhances the activity 
of GSK-3 recovered from APC-deficient colorectal carcinoma cells. 
 
2-3-4. Wnt3a induces Axin/APC dissociation 
 
In the canonical Wnt pathway, β-catenin is constitutively phosphorylated 
by GSK-3 within the Axin complex and targeted for degradation. APC interaction 
with Axin is required for β-catenin phosphorylation and destabilization. Binding of 
Wnts to the surface receptor complex leads to inhibition of GSK-3 activity through 
an as yet poorly characterized mechanism (Clevers, 2006; MacDonald et al., 
2009). As our data show that APC enhances GSK-3 activity in general and can 
specifically enhance GSK-3 phosphorylation of ß-catenin within the Axin complex  
	   39 
 
Figure 2-4 
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Figure 2-4. Wnt signaling disrupts the interaction between APC and Axin. L 
cells were treated with Control or Wnt3a conditioned medium (CM) for indicated 
times.  (A) APC was immunoprecipitated from control and Wnt3a treated cells 
and samples were immunoblotted for Axin or APC. For image quantification, Axin 
was normalized to APC and then all lanes were normalized to control (Lane 1). 
Error bars represent standard error of the mean of four independent experiments. 
(B) Lysates from panel A were immunoblotted for β-catenin, Axin, APC and 
GAPDH. β-catenin accumulation in response to Wnt activation correlates with 
Axin/APC dissociation in panel A. (C) Wnt3a does not affect GSK-3 association 
with Axin. 
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(Figure 2-3), we hypothesized that Wnt signaling may reduce GSK-3 activity by 
inducing dissociation of APC from the Axin complex. To test this, we treated L 
cells with control or Wnt3a conditioned medium for up to 2 hours, 
immunoprecipitated endogenous APC, and detected endogenous APC-
associated Axin. The amount of Axin associated with APC was dramatically 
reduced by 30 minutes, and interaction was not restored even after 2 hours 
(Figure 2-4A). Similar results were obtained when Axin was immunoprecipitated, 
when purified recombinant Wnt3a was used instead of Wnt3a conditioned 
medium, and when 293T cells were treated with Wnt3a (data not shown). 
Importantly, observation of Wnt-induced Axin/APC dissociation was sensitive to 
lysis and IP conditions, especially the pH of the lysis buffer (see methods). The 
amount of GSK-3 associated with Axin did not change under these conditions 
(Figure 2-4C). Interestingly, the onset of β-catenin accumulation correlated with 
APC/Axin dissociation (Figure 2-4B). Taken together, these results show that 
activation of the Wnt pathway causes APC/Axin dissociation, and this may 
contribute to reduced GSK-3 activity and subsequent β-catenin stabilization. 
 
2-3-5. Axin binding to LRP6 causes APC dissociation 
 
The Wnt co-receptor LRP6 is phosphorylated in response to canonical 
Wnt ligands, and LRP6 phosphorylation promotes direct interaction with Axin 
(Mao et al., 2001; Tamai et al., 2004; Zeng et al., 2005). As Wnt3a causes  
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dissociation of APC from Axin, we hypothesized that the recruitment of Axin to 
phosphorylated LRP6 may displace APC from the Axin complex. Deletion of the 
N-terminal extracellular domain of LRP6 results in a constitutively active LRP6 
fragment (CA-LRP6) that is phosphorylated by GSK-3, interacts with Axin, and 
results in β-catenin stabilization and activation of Wnt target genes (Tamai et al., 
2004; Zeng et al., 2005), (Supplemental Figure S2-8). We found that co-
expression of CA-LRP6 and Axin markedly reduces the relative amount of APC 
associated with Axin (Figure 2-5A, compare lanes 3,4). In addition, inhibition of 
GSK-3 with LiCl reduced the Axin-CA-LRP6 interaction and restored APC-Axin 
interaction (Figure 2-5A, lanes 3-5), consistent with the known role for GSK-3 in 
phosphorylation and activation of LRP6. Conversely, LiCl had no effect on Axin-
APC association in the absence of the CA-LRP6 fragment (Figure 2-5D). 
Importantly, the nonfunctional LRP6 mutant LRP6∆N1Ab did not recruit Axin or 
activate Wnt signaling, as shown previously (Tamai et al., 2004; Zeng et al., 
2005), (Supplemental Figure S2-8), and had no effect on Axin-APC interaction 
(Figure 2-5C). Importantly, there was no detectable APC association with CA-
LRP6 despite significant Axin association with CA-LRP6 (Figure 2-5A, lane 2). 
These results show that recruitment of Axin to the activated form of LRP6 
displaces APC from the Axin complex, and suggest that Wnt induced Axin-LRP6 
interaction causes APC dissocation.  
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Figure 2-5 
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Figure 2-5. LRP6 binding to Axin causes APC dissociation. (A) A 
constitutively active form of LRP6 (VSV-G-CA-LRP6) was expressed in 293T 
cells with Axin, and cell lysates were immunoprecipitated with antibodies to VSV-
G, Axin, or control antibody, and then immunoblotted for APC, Axin, or VSV-G-
CA-LRP6. Axin IP samples were adjusted for equal loading of Axin. Constitutively 
active LRP6 reduces APC association with Axin (compare lanes 3,4). LiCl 
(15mM) reduces LRP6/Axin association and restores APC/Axin association 
(Lane 5).  APC association with CA-LRP6 was not detected (Lane 2). (B) 
Western Blot analysis of APC, Axin and CA-LRP6 in lysates used for 
immunoprecipitation in Panel A. Co-expression of Axin and CA-LRP6, but not 
LRP6ΔN1ab, increased Axin levels for unclear reasons. (C) The 
unphosphorylatable VSV-G-LRP6ΔN1ab does not associate with Axin and does 
not affect Axin/APC interaction. (D)  15mM LiCl alone does not affect Axin/APC 
interaction.    
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2-4. Discussion 
 
 In this study, we defined a role for APC in the regulation of GSK-3 and 
GSK-3 dependent pathways, including Glycogen Synthase, mTOR, and Wnt 
signaling (Figure 2-6A).  
APC mutations associated with colorectal cancer strongly activate Wnt 
signaling, and here we show that these mutations also activate mTOR, a 
metabolic sensor that is aberrantly activated in many cancers (Zoncu et al., 
2011). As GSK-3 suppresses both Wnt and mTOR pathways (Inoki et al., 2006; 
MacDonald et al., 2009), our demonstration that APC enhances GSK-3 activity 
provides a mechanistic link between APC loss of function and activation of these 
two downstream signaling pathways. In support of this mechanism, tumor 
formation in mice with similar APC mutations is blocked by mTOR inhibitors 
(Fujishita et al., 2008; Koehl et al., 2010). Furthermore, bladder specific β-catenin 
stabilization synergizes with PTEN deletion, which activates mTOR, to promote 
bladder cancer in mice (Ahmad et al., 2011).  Taken together, these data support 
the hypothesis that mTOR activation is required for APC-mediated tumor 
formation and suggest mTOR as a potential therapeutic target for treatment of 
cancers resulting from APC mutations.   
We also show that APC promotes phosphorylation of Glycogen Synthase 
by GSK-3, implicating APC in glucose metabolism and glycogen synthesis for the 
first time. Interestingly, addition of Wnt ligands or knockdown of Axin activates β-
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catenin and mTOR but does not affect GS phosphorylation. These data suggest 
APC and GSK-3 regulation of GS is independent of the Axin complex, unlike 
regulation of β-catenin and mTOR. Axin knockdown in Drosophila S2 cells 
increases glycogen levels but this may be through regulation of the Drosophila c-
Cbl Associated Protein (DCAP) rather than GSK-3 and GS (Yamazaki and 
Yanagawa, 2003). 
In addition to regulating Wnt, Glycogen Synthase, and mTOR signaling, 
APC and GSK-3 both promote mitotic spindle formation, negatively regulate 
MAPK/ERK and BMP signaling (Figure 2-6A), and regulate apoptosis (Forde and 
Dale, 2007; Fuentealba et al., 2007; Fukuda et al., 2010; Hanson and Miller, 
2005; Miclea et al., 2011; Park et al., 2006; Wang et al., 2006). Taken together, 
these observations suggest a widespread role for APC in the regulation of GSK-3 
dependent signaling. Future studies are needed to determine whether APC 
regulates additional GSK-3 dependent pathways such as the Notch, Hedgehog, 
and NF-κB pathways.  
The finding that APC enhances GSK-3 activity prompted us to ask 
whether APC is also regulated by Wnt signaling to reduce GSK-3 activity. 
Canonical Wnts reduce GSK-3 activity through unknown mechanisms, and this is 
critical for β-catenin stabilization (Cook et al., 1996; Ding et al., 2000). We find 
that Wnts rapidly induce APC dissociation from Axin, in close temporal 
correlation with β-catenin accumulation. Furthermore, Axin interaction with 
activated LRP6, the Wnt co-receptor, causes APC dissociation. Therefore we  
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Figure 2-6 
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Figure 2-6. Model.  (A) APC negatively regulates multiple signaling pathways, 
including the Wnt, Glycogen Synthase, mTOR, ERK, and BMP pathways by 
enhancing GSK-3 activity.  (B)  Wnts disrupt the Axin/APC interaction to reduce 
GSK-3 activity and thus activate downstream signaling 
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propose that Wnt-induced Axin recruitment to LRP6 displaces APC, reducing 
GSK-3 activity and activating downstream signaling (Figure 2-6B).  Consistently, 
Wnt-1 induces membrane localization of Axin and GSK-3, but not APC (Chen et 
al., 2006).  
Previous work showed APC is required for β-catenin phosphorylation and 
degradation, and this was attributed to APC recruiting β-catenin to the Axin 
complex (Hinoi et al., 2000; Yang et al., 2006). While this work is compatible with 
our findings, we also find that APC enhances GSK-3 activity towards multiple 
substrates, including β-catenin. Consistently, deletion of the RGS domain of Axin, 
which binds APC, reduces GSK-3 activity and activates Wnt signaling 
(Hedgepeth et al., 1999). Interestingly, APC also enhances activity of 
topoisomerase IIα (Wang et al., 2008), possibly suggesting a novel widespread 
function for APC in regulating enzymatic activity. 
APC also blocks dephosphorylation of β-catenin by protein phosphatase-
2A (PP2A) (Su et al., 2008). Therefore Wnt induced APC-Axin dissociation may 
stabilize β-catenin by both reducing GSK-3 activity and allowing PP2A mediated 
β-catenin dephosphorylation. Interestingly, this mechanism parallels Glycogen 
Synthase activation by Insulin which induces both inhibition of GSK-3 and 
dephosphorylation of Glycogen Synthase by protein phosphatase-1 (Brady and 
Saltiel, 2001). 
Recent work has shown that Wnt signaling induces sequestration of the 
GSK-3 into multivesicular bodies, and this was suggested as a mechanism for 
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attenuating phosphorylation and degradation of β-catenin (Taelman et al., 2010). 
However, that work examined GSK-3 several hours after stimulation with Wnts, 
whereas we observe dissociation of APC from Axin within 30 minutes, closely 
correlated with accumulation of β-catenin protein. Because of the different time 
scales, the work of Taelman et al is not incompatible with our findings, and may 
represent a later consequence of Wnt signaling.  
GSK-3 negatively regulates mTOR by phosphorylating Tuberous Sclerosis 
Complex 2 (TSC2).  TSC2 associates with the Axin complex, and canonical Wnts 
activate mTOR by inhibiting GSK-3 and reducing TSC2 phosphorylation (Inoki et 
al., 2006). As we show APC enhances GSK-3 activity and negatively regulates 
mTOR, Wnt-induced APC dissociation from Axin also provides a mechanism for 
how Wnts activate mTOR. 
Since APC regulates multiple GSK-3 dependent processes, and is 
regulated by Wnts, additional studies are needed to determine whether APC can 
be regulated to reduce GSK-3 activity in other contexts.  For example, during 
hippocampal development, axonal-dendritic polarity is established by selection of 
one of several minor neurites to grow into the mature axon (Dotti et al., 1988).  
This process involves localized inhibition of GSK-3 through unknown 
mechanisms (independent of S9/21 phosphorylation), and concomitant spatial 
relocation of APC (Gartner et al., 2006; Jiang et al., 2005; Shi et al., 2004). Thus, 
APC sequestration might reduce GSK-3 activity to promote hippocampal neurite 
outgrowth.   
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In conclusion, we demonstrate novel roles for APC as a negative regulator 
of both Glycogen Synthase and mTOR, like GSK-3, and uncover a novel ability 
of APC to directly enhance GSK-3 activity. We also show that Wnts induce APC-
Axin dissociation, suggesting a new mechanism for how Wnts decrease GSK-3 
activity. Further studies are needed to investigate a role for APC in additional 
GSK-3 dependent processes, and to determine whether APC is regulated in 
other contexts to reduce GSK-3 activity. 
 
2-5. Materials and Methods 
 
 2-5-1. Cell culture, conditioned medium and transfections 
 
HEK293 cells (ATCC #CRL-1573), HEK293T OT-Luciferase cells (Phiel et 
al., 2001), L cells (ATCC #CRL-2648), L-Wnt3a cells (ATCC #CRL-2647), and 
SW480 cells (ATCC #CCL-228) were cultured in Dulbecco’s Modified Eagle 
Medium (GIBCO #11965) supplemented with 10% Fetal Bovine Serum (Hyclone 
#SH30071.03) and 1% penicillin/streptomycin (GIBCO #15140). Insulin was 
purchased from Sigma (#I9278). Control and Wnt3a conditioned media were 
prepared from L and L-Wnt3a cells respectively according to ATCC instructions.  
Cells were transfected 24 hours after plating using Lipofectamine 2000 
(Invitrogen #11668) for plasmids or Lipofectamine RNAiMax (Invitrogen #13778) 
for siRNAs according to manufacturer’s instructions.  Transfections were done in 
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Opti-MEM Reduced Serum Medium (GIBCO #31985).   
 
2-5-2. Plasmids and siRNAs 
 
Myc-SAMP (APC 1211-2075) in pEF-BOS vector was provided by Akira 
Kikuchi (Hinoi et al., 2000).  VSV-G-LRP6DN1 (constitutively active LRP6) and 
VSV-G-LRP6ΔN1ab (nonfunctional LRP6) both in pCS2+ vector were provided 
by Xi He (Tamai et al., 2004). Axin in pCS2+MT vector was described previously 
(Hedgepeth et al., 1999). APC in pCMV vector was provided by Bert Vogelstein 
and Kenneth Kinzler (Smith et al., 1994).  Myc-tagged stabilized β-catenin 
(T41A/S45A) in pCS2+MT vector was provided by Ed Morrisey (Xu et al., 2000). 
Axin and GFP shRNAs expressed from pSUPER vector were provided by Xiao-
Fan Wang (Guo et al., 2008). APC siRNA expressed from pSUPER vector 
(pH1iAPC729) was provided by Jean Schneikert (Schneikert and Behrens, 
2006). The following siRNAs were purchased from Applied Biosystems and 
transfected at a final concentration of 75nM; Silencer Negative Control #1 
(Catalog #AM4635), APC (siRNA ID #42812), APC (siRNA ID #s1435).   
 
2-5-3. Western blotting, immunoprecipitations and luciferase assays.  
 
Cells were lysed in buffer containing 20mM Tris pH 7.5, 140mM NaCl, 
1mM EDTA, 10% glycerol, 1% Triton X-100, 1mM DTT, 50mM NaF, and 
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protease inhibitor cocktail (Sigma P8340), phosphatase inhibitor cocktail #1 
(Sigma P2850) and #2 (Sigma P5726) or #2 and #3 (Sigma P0044) used 1:100 
each. Lysis buffer used in Figure 2-4 contained 20mM Tris pH 8.0 instead of pH 
7.5. Supernatants were collected after centrifugation at 13,000 rpm for 5 min at 
4oC.  For immunoprecipitation, lysates were incubated with antibodies to Axin 
(Kofron et al., 2001), APC (Santa Cruz #sc-896), VSV-G (Sigma #V4888) or 
control IgG (Thermo Scientific #31235) for 2 hrs, and then Protein G Agarose 
beads (Invitrogen #15920) were added for an additional 2 hrs. Antibody-bound 
beads were washed with lysis buffer 3 times for 5 min each and resuspended in 
standard 2X Laemmli Sample Buffer.  All steps were done at 4oC.  Samples were 
heated for 5 min at 95oC before SDS-PAGE and western blot analysis using the 
following antibodies from Cell Signaling: phospho-Glycogen Synthase (#3891), 
Glycogen Synthase (#3893), phospho-Akt (#4058), phospho-GSK-3 (#9331), 
Axin (#3323), phospho-S6 (#4858), total S6 (#2317), phospho-β-catenin (#9561), 
GAPDH (#2118), or antibodies to GSK-3 (Calbiochem #368662), APC (Santa 
Cruz #sc-896 or  Abcam #ab58), myc (Sigma #C3956), β-catenin (BD 
Transduction Laboratories #610153), VSV-G (Sigma #V4888), Axin (Kofron et 
al., 2001), phospho-Tau (PHF-1 antibody provided by Peter Davies (Greenberg 
et al., 1992)), or total Tau (T14/46 antibodies provided by Virginia Lee).  For 
luciferase assay, cells were lysed in 1X Promega Passive Lysis Buffer (Promega 
E194A) and luciferase assay was performed using the Promega Dual Luciferase 
Reporter Assay System (Promega #E1910) according to manufacturer’s 
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instructions.   
 
2-5-4. In vitro kinase reactions and image quantification 
 
Purified recombinant proteins were incubated in kinase reaction buffer 
(100mM Tris pH 7.5, 5mM DTT, 10mM MgCl2, 100µM ATP) for 10 min at 30oC.  
Reactions were stopped by adding standard 2X Laemmli Sample Buffer and 
incubating at 95oC for 5 min.  The following protein concentrations were used; 
80nM GST-SAMP, 100nM His-β-catenin, 100nM His-Axin, 100nM Tau, 80nM 
BSA (Sigma #A9647), 2 units/µl GSK-3 (New England Biolabs #P6040), 4 
units/µl CKI (New England Biolabs #P6030). Western blot images were 
quantified using ImageJ software. For Supplemental Figure S2-7, cells were 
lysed in standard RIPA buffer, immunoprecipitated with anti-GSK-3 antibody, and 
GSK-3 kinase activity assay was performed as previously described (Klein and 
Melton, 1996). 
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2-6. Supplemental Material 
 
Supplemental Figure S2-1 
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Supplemental Figure S2-1. GSK-3 inhibition reduces GS phosphorylation 
and activates mTOR. (A) CHIR99021 (6µM), or (B) 6-Bromoindirubin-3’-oxime 
(5µM) reduces GS phosphorylation (Ser641) and increases S6 phosphorylation 
(Ser235/236) in 293T cells. 
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Supplemental Figure S2-2 
 
 
 
 
 
 
 
 
 
 
 
 
	   58 
 
Supplemental Figure S2-2. APC knockdown with a second, non-
overlapping siRNA reduces GS phosphorylation and activates mTOR. APC 
was knocked down in 293T cells by transfection of Applied Biosystems APC 
siRNA ID #s1435 which targets a non-overlapping sequence compared to 
Applied Biosystems APC siRNA ID #42812 used in Figures 2-1 and 2-2. APC 
knockdown with this second siRNA also reduces GS phosphorylation and 
increases S6 phosphorylation. 
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Supplemental Figure S2-3 
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Supplemental Figure S2-3. Downstream Wnt pathway activation does not 
affect GS or S6 phosphorylation. Stabilized ß-catenin (T41A/S45A) expressed 
in 293T OT Luciferase cells robustly activated the TOPFLASH Wnt reporter (A), 
but did not affect phospho-GS (Ser641) or phospho-S6 (Ser235/236) (B). Error 
bars represent standard error of the mean. 
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Supplemental Figure S2-4 
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Supplemental Figure S2-4. Insulin-dependent inhibition of GS 
phosphorylation is not enhanced by concomitant APC knockdown. HEK293 
cells stably expressing siRNA targeting APC and control HEK293 cells were 
treated with 2µM insulin for 30 min. APC knockdown reduces GS 
phosphorylation in the absence of insulin and insulin reduces GS 
phosphorylation in control HEK293 cells. Combined APC knockdown and insulin 
treatment does not further reduce GS phosphorylation. 
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Supplemental Figure S2-5 
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Supplemental Figure S2-5. Insulin does not induce phosphorylation of 
GSK-3 associated with the Axin/APC complex. 293T cells were treated with 
2µM insulin for 30 min followed by immunoprecipitation of endogenous protein 
using control IgG, APC, or Axin antibodies. (A) Insulin induced serine-9 
phosphorylation of GSK-3ß in whole cell lysates but not GSK-3ß associated with 
immunoprecipitated APC or Axin, which detects primarily the Axin/APC complex. 
The longer exposures show background GSK-3ß or phospho-GSK-3ß present in 
immunoprecipitates to make it clear that, at the limit of detection, there is no 
change in phosphorylation of GSK-3ß associated with this complex, as described 
previously (Ding et al., 2000). (B) Immunoblot of APC and Axin present in APC 
IPs. (C) Immunoblot of Axin in Axin IPs. (D) Insulin does not affect Axin or APC 
levels in the input lysates. 
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Supplemental Figure S2-6 
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Supplemental Figure S2-6. Glycogen Synthase phosphorylation is not 
regulated by Wnt3a or Axin. (A) L cells were treated with control or Wnt3a 
conditioned medium for up to two hours. Samples are the same as those used in 
Figure 2-4B. Wnt3a stabilized β-catenin (see Figure 2-4B) but did not affect GS 
phosphorylation. (B) 293T cells were transfected with GFP or Axin shRNA. Axin 
knockdown increased S6 phosphorylation but did not affect GS phosphorylation. 
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Supplemental Figure S2-7 
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Supplemental Figure S2-7. Wild type APC expression enhances GSK-3 
activity recovered from APC deficient colorectal carcinoma cells. (A) 
Endogenous GSK-3 was immunoprecipitated in triplicate from untreated or ZnCl2 
treated (150µM, 24 hrs) HT29-APC and HT29-ßgal cells. Immunoprecipitates 
from each group were split and each sample was treated with buffer or the GSK-
3 inhibitor SB216763 (10µM). A peptide derived from Glycogen Synthase (GS-2 
peptide) was added to the immunoprecipitates (20 µM) and GSK-3 activity was 
assayed by 32P -incorporation. Kinase reactions were run in triplicate and mean 
activity is shown for each group. Error bars represent standard error of the mean. 
“Control IP” indicates that antirabbit IgG antibody was used for 
immunoprecipitation. (B) GSK-3 present in the IPs (done in triplicate) used for the 
GSK-3 activity assay in panel A. (C) Zinc induced full length APC in HT-29-APC 
cells, as shown by immunoblot of whole cell lysates. 
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Supplemental Figure S2-8 
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Supplemental Figure S2-8. Constitutively active LRP6 activates 
downstream Wnt signaling. Expression of VSV-G tagged constitutively active 
LRP6 (VSV-G-CA-LRP6), but not the nonfunctional, unphosphorylatable VSV-G-
LRP6ΔN1ab fragment, elevated β-catenin levels (A) and activated the 
TOPFLASH Wnt reporter (B) in 293T OT Luciferase cells. Error bars represent 
standard error of the mean. 
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CHAPTER 3: ONCOGENIC MUTATIONS IN ADENOMATOUS POLYPOSIS 
COLI (Apc) ACTIVATE MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 
1 (mTORC1) 
 
3-1. Summary 
 
Adenomatous polyposis coli (APC) is a negative regulator of the Wnt 
pathway that is mutated in familial adenomatous polyposis (FAP) and most 
sporadic colorectal cancers. Apc mutations cause accumulation of the Wnt 
signaling effector ß-catenin and sustained activation of Wnt target genes. 
However, recent evidence suggests that additional downstream effectors may 
contribute to Apc mutant phenotypes. We previously identified a mechanism by 
which APC suppresses mTORC1 in cultured cells. As mTORC1 activation is 
associated with inherited polyposis syndromes such as Peutz-Jeghers and 
Cowden’s syndromes, we hypothesized that oncogenic Apc mutations may 
activate mTORC1 and that this may contribute to Apc mutant phenotypes. Here 
we report marked mTORC1 activation in zebrafish and mice harboring oncogenic 
Apc mutations. We show that mTORC1 contributes to several Apc mutant 
phenotypes, as inhibition of mTORC1 improves survival, reverses liver 
hyperplasia, and partially rescues circulatory defects in the Apc mutant zebrafish.  
 
*The text and figures in Chapter 3 are presented as submitted for publication in 
March 2013 (Valvezan AJ, Huang J, Lengner CJ, Pack M, Klein PS. Oncogenic 
mutations in Adenomatous polyposis coli (Apc) activate mechanistic target of 
rapamycin complex 1(mTORC1)). 
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Furthermore, combined inhibition of mTORC1 and Wnt/ß-catenin signaling 
rescues defects in anterior-posterior morphogenesis. Thus we identify 
widespread roles for aberrant mTORC1 activation in phenotypes resulting from 
Apc mutation. Simultaneous inhibition of Wnt and mTORC1 signaling may 
represent an effective strategy for treating colorectal cancers resulting from APC 
mutations. 
 
3-2. Introduction 
 
 Colorectal cancer (CRC) is the third most common cancer and second 
leading cause of cancer related death in the United States, responsible for over 
50,000 deaths annually in the US and over 600,000 worldwide ( U.S. Cancer 
Statistics Working Group, 2013). 80% of sporadic CRCs result from mutations in 
Adenomatous Polyposis Coli (APC) (Kinzler and Vogelstein, 1996; Cancer 
Genome Atlas Network, 2012).  Patients with germline APC mutations develop 
Familial Adenomatous Polyposis (FAP) which is marked by hundreds to 
thousands of adenomatous colon polyps and progression to invasive carcinomas 
(Groden et al., 1991; Kinzler et al., 1991; Miyoshi et al., 1992). APC mutations 
occur within a mutation cluster region (MCR) and result in expression of a 
truncated protein that lacks the C-terminal half (Miyoshi et al., 1992). Intestinal 
cells in humans, mice, and rats with these mutations undergo loss of 
heterozygosity, thus initiating tumor development (Amos-Landgraf et al., 2007; 
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Haramis et al., 2006; Kinzler and Vogelstein, 1996; Su et al., 1992).  
As a negative regulator of the Wnt signaling pathway, APC is a core 
component of the degradation complex that mediates the turnover of ß-catenin. 
Apc mutations therefore stabilize and constitutively activate Wnt/ß-catenin 
signaling, a key step in the development of CRCs (Korinek et al., 1997; 
MacDonald et al., 2009; Morin et al., 1997; Munemitsu et al., 1995). 
Overexpression of ß-catenin in the colon leads to adenoma formation 
(Romagnolo et al., 1999) whereas knocking down ß-catenin reduces adenoma 
size and frequency (Foley et al., 2008; Scholer-Dahirel et al., 2011). In addition, 
CRCs with wild-type Apc frequently have stabilizing mutations in ß-catenin (Morin 
et al., 1997; Polakis, 2000), providing compelling evidence for the role of ß-
catenin in colorectal carcinogenesis.  
However, several groups have reported that nuclear localization of ß-
catenin, which is required to activate Wnt signaling, is infrequently observed in 
early adenomas of patients with FAP, sporadic human polyps, and 
microadenomas in a rat model of FAP, despite Apc loss of heterozygosity (LOH) 
and elevated cytosolic ß-catenin (Amos-Landgraf et al., 2007; Anderson et al., 
2002; Blaker et al., 2004; Kobayashi et al., 2000). In addition, defects in intestinal 
differentiation were observed in zebrafish Apcmcr mutants without detectable 
nuclear ß-catenin or activation of a Wnt transcription reporter (Phelps et al., 
2009b). While the absence of detectable nuclear ß-catenin in adenomas could 
also reflect the sensitivity of the detection methods, the observations have 
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nevertheless led to the identification of additional steps required for nuclear 
translocation of ß-catenin, including activation of Ras and Rac1 (Phelps et al., 
2009b; Zhu et al., 2011).   
These observations have also raised the possibility that additional 
effectors downstream of APC may contribute to Apc loss of function phenotypes 
(Phelps et al., 2009a; Phelps et al., 2009b). APC has Wnt/ß-catenin-independent 
roles including regulation of apoptosis, microtubule dynamics, regulation of 
retinoic acid biosynthesis, and cell-cell adhesion (Hanson and Miller, 2005; 
Phelps et al., 2009a). We previously found that APC directly enhances the 
activity of Glycogen Synthase Kinase-3 (GSK-3) (Valvezan et al., 2012). GSK-3 
in turn negatively regulates mechanistic Target of Rapamycin Complex 1 
(mTORC1) (Inoki et al., 2006) and thus we found that APC, through GSK-3, 
suppresses mTORC1 activity in cultured cells (Valvezan et al., 2012). mTORC1 
is a metabolic sensor and translational regulator, that promotes cell growth and 
proliferation, and is aberrantly active in many cancers (Laplante and Sabatini, 
2012). Thus we hypothesized that oncogenic Apc mutations may activate 
mTORC1, and that this activation may contribute to Apc loss of function 
phenotypes.  
To investigate mTORC1 activity downstream of APC, we have examined 
oncogenic Apc mutations in zebrafish and mice. Homozygous Apc mutant mice 
die before gastrulation (Fodde et al., 1994), whereas homozygous mutant 
zebrafish (apcmcr/mcr zebrafish) survive until early larval stages (Hurlstone et al., 
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2003). Apc mutant zebrafish have multiple developmental defects including 
impaired circulation, hyperproliferation of the cardiac cushions, enlarged livers, 
and defects in morphogenesis of the anterior-posterior axis resulting in severe 
body curvature (Goessling et al., 2008; Hurlstone et al., 2003). These 
observations indicate a critical role for APC in development of multiple organs 
and tissues.  
Here we show that mTORC1 is aberrantly activated in Apcmcr/mcr zebrafish 
and that mTORC1 inhibition attenuates multiple phenotypes in Apc mutants, 
indicating that mTORC1 activation contributes to these phenotypes. We also find 
that mTORC1 is robustly activated in intestinal adenomas in Apcmin mice. Taken 
together, these data suggest that APC mutations function in part by activating 
mTORC1. 
 
3-3. Results 
 
3-3-1.Oncogenic Apc mutation activates mTORC1   
 
We previously found that APC directly enhances the kinase activity of 
GSK-3 (Valvezan et al., 2012). GSK-3 inhibits mTORC1 activity (Inoki et al., 
2006) and thus knocking down APC reduces GSK-3 activity and activates 
mTORC1 in cultured cells (Valvezan et al., 2012). We therefore hypothesized 
that oncogenic APC mutations should activate mTORC1 in vivo. For these  
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Figure 3-1 
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Figure 3-1. Activation of mTORC1 in apcmcr/mcr zebrafish. Western blot 
analysis using antibodies to phosphorylated S6, indicating mTORC1 activity, or 
total S6 on whole embryo lysates from pooled wild type and heterozygous 
apcmcr/+ zebrafish or homozygous apcmcr/mcr zebrafish at 3 or 4 days post 
fertilization. mTORC1 activity is increased in the homozygous apcmcr/mcr zebrafish. 
(B) Immunohistochemical staining of sagittal sections from wild type or 
homozygous apcmcr/mcr zebrafish at 3 dpf using antibodies to phosphorylated or 
total S6 and counterstained with DAPI. mTORC1 is aberrantly active in multiple 
mesodermal and endodermal derivatives in the homozygous apcmcr/mcr zebrafish.  
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studies we used Apcmcr zebrafish, which contain a previously characterized 
mutation that causes a premature stop codon within the mutation cluster region 
(mcr) of Apc, analgous to truncating mutations typically found in human 
colorectal cancers (Haramis et al., 2006; Hurlstone et al., 2003). We compared 
mTORC1 activity in apcmcr/mcr zebrafish to wild type and heterozygous zebrafish. 
Homozygous Apc mutation activates mTORC1, as assessed by western blotting 
whole embryo lysates for phosphorylation of ribosomal protein S6, a well 
established readout of mTORC1 activity (Laplante and Sabatini, 2012). 
Phosphorylated S6 is increased in homozygous mutants at 3 and 4 days post 
fertilization (dpf) compared to pooled wild type and heterozygous fish, without a 
change in total S6 (Figure 3-1A). To assess tissue specific changes in mTORC1 
activity, we also performed immunohistochemistry on larvae fixed at 3 dpf. 
Immunostaining for phospho-S6 reveals broadly increased mTORC1 activity in 
multiple mesodermal and endodermal derivatives (Figure 3-1B). These data 
indicate that an oncogenic Apc mutation activates mTORC1.  
 
3-3-2. mTORC1 inhibition extends the survival of apcmcr/mcr zebrafish  
 
To test whether aberrantly active mTORC1 contributes to apcmcr/mcr 
phenotypes, we asked whether mTORC1 inhibition rescues phenotypes in these 
fish. Torin1, a direct inhibitor of mTOR kinase activity (Thoreen et al., 2009), was 
added to developing embryos at 24 hpf and survival was assessed daily. Vehicle  
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Figure 3-2 
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Figure 3-2. mTORC1 inhibition extends survival in apcmcr/mcr zebrafish. (A) 
apcmcr/mcr zebrafish were treated with vehicle or Torin1 (250nM) starting at 24 hpf. 
The percent of fish alive was recorded every 24 hours. (B) Torin1 (250nM) was 
added between 0-6 hpf, at 24 hpf, at 36 hpf, or between 48-60 hpf. The percent 
of Torin1 treated fish alive at 4 dpf was normalized to the percent of vehicle 
treated fish alive at 4 dpf. (C) Western blot analysis using antibodies to phospho-
S6 or total S6 on whole embryo lysates from pooled 3 day old wild type and 
heterozygous apcmcr/+ zebrafish or homozygous apcmcr/mcr zebrafish treated with 
vehicle or Torin1. Torin1 treatment under these conditions (250nM) reduces 
mTORC1 activity in homozygous apcmcr/mcr zebrafish to levels similar to vehicle 
treated wild type/heterozygous fish. (D) Survival curves of apcmcr/mcr zebrafish 
treated with vehicle or Rapamycin (200nM) starting at 24 hpf. (E) Western blot 
analysis as in (C) on fish treated with vehicle or Rapamycin. Error bars in (A,D) 
represent standard error of the mean and p-values were calculated using the log-
rank (Mantel-Cox) test.  
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treated apcmcr/mcr zebrafish larvae die 3-4 days post fertilization (dpf) while 
treatment with Torin1 extends their survival by up to 24 hours, with approximately 
40% of Torin1 treated larvae surviving at 4 dpf compared to ~10% of vehicle 
treated controls (Figure 3-2A; p<0.0001). We also assessed the effect of adding 
Torin1 at different developmental stages. Adding Torin1 at 0-6 hpf or 24hpf had 
similar effects on survival: Approximately 3.5 times as many Torin1 treated 
apcmcr/mcr zebrafish were alive at 4 dpf compared to vehicle treated apcmcr/mcr 
zebrafish when treatment was started at either 0-6 hpf or 24 hpf (Figure 3-2B). 
Treatment at 36 hpf or later was less effective (Figure 3-2B). Importantly, Torin1 
treatment reduced mTORC1 activity in homozygous apcmcr/mcr zebrafish to levels 
similar to vehicle treated wild type/heterozygous fish (Figure 3-2C), highlighting 
the role for aberrant mTORC1 activation resulting from oncogenic Apc mutation. 
Treatment with Rapamycin, an allosteric inhibitor of mTORC1 that acts through a 
distinct mechanism (Sarbassov et al., 2006), also extends survival of apcmcr/mcr 
zebrafish (Figure 3-2D). These data suggest that aberrant mTORC1 activation 
resulting from oncogenic Apc mutation contributes to early lethality in apcmcr/mcr 
zebrafish. 
 
3-3-3. mTORC1 inhibition improves circulation in apcmcr/mcr zebrafish 
 
apcmcr/mcr zebrafish have dramatically reduced circulation compared to wild 
type fish at 2-3 dpf  (Supplemental videos 3-1 through 3-4)  
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Figure 3-3 
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Figure 3-3. mTORC1 inhibition improves circulation in apcmcr/mcr zebrafish. 
(A) apcmcr/mcr zebrafish were treated with vehicle or Torin1 (250nM) and the rate 
of blood flow through the dorsal aorta was measured using high speed 
videomicroscopy in unanesthetized larvae at 2-3 dpf. Blood flow phenotypes 
were categorized according to flow rate as indicated in the figure. Representative 
videos for each scoring category can be found in online supplemental material 
(Supplemental videos 1-4). (B) Rapamycin also improves circulation in apcmcr/mcr 
zebrafish. (C,D) Torin1 and Rapamycin treatment do not increase the heart rate 
of apcmcr/mcr zebrafish.  
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(Hurlstone et al., 2003). We used high speed videomicroscopy to measure blood 
flow through the dorsal aorta; approximately half of vehicle treated fish had no 
circulation through the dorsal aorta and approximately 75% had a flow rate of 
less than 0.2 mm/second (Figure 3-3A). Torin1 treatment improves circulation, 
resulting in a flow rate greater than 0.2 mm/second in approximately 50% of 
mutants, and reducing the percent of mutants with no circulation to approximately 
25% (Figure 3-3A). Rapamycin similarly doubled the percent of mutants with flow 
greater than 0.2 mm/second and halved the percent of mutants with no 
circulation (Figure 3-3B). Representative videos showing blood flow through the 
dorsal aorta in wild type fish and each of the three categories used for scoring 
apcmcr/mcr zebrafish can be found in online supplemental material. Torin1 and 
Rapamycin did not increase the heart rate of the apcmcr/mcr zebrafish (Figure 3-
3C,D). These data indicate that mTORC1 activation in apcmcr/mcr zebrafish 
contributes to the reduced circulation phenotype.  
 
3-3-4. mTORC1 inhibition rescues liver hyperplasia in heterozygous apcmcr/+ 
zebrafish  
 
Heterozygous apcmcr/+ zebrafish have enlarged livers by 3 dpf due to an 
increase in the number of hepatocytes (Figure 3-4) (Goessling et al., 2008). To 
ask whether this phenotype can be rescued by mTORC1 inhibition, we crossed 
heterozygous apcmcr/+ zebrafish to lfabp:RFP fish, which express red fluorescent  
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Figure 3-4 
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Figure 3-4. mTORC1 inhibition rescues liver hyperplasia in heterozygous 
apcmcr/+ zebrafish. Lfabp:rfp zebrafish, which express liver specific RFP, were 
mated with apcmcr/+ zebrafish. (A) Resulting progeny (expected 50% apc+/+, 50% 
apcmcr/+) were treated with vehicle or Torin1 and the percent of fish with normal or 
enlarged livers at 3-4 dpf was recorded. Approximately 50% of vehicle treated 
fish had enlarged livers as described previously (Goessling et al., 2008). Torin1 
reduces the percent of fish with enlarged livers. (B) Rapamycin similarly rescues 
liver enlargement. (C) Representative pictures showing liver enlargement in 
vehicle treated heterozygous apcmcr/+ zebrafish but not in Torin1 or Rapamycin 
treated heterozygotes. (D) Liver size correlates closely with genotype in vehicle 
treated embryos as described previously (Goessling et al., 2008), but 
heterozygous apcmcr/+ embryos account for approximately half of Torin1 treated 
embryos with normal size livers, confirming Torin1 reduces liver size in 
heterozygous apcmcr/+ embryos. (E) The number of RFP positive cells per embryo 
was measured by flow cytometry. Vehicle treated apcmcr/+ zebrafish had 
approximately 75% more hepatocytes than vehicle treated wild type fish, and this 
was rescued by Torin1 treatment.   
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protein under control of the liver specific liver fatty acid binding protein (lfabp) 
promoter (Her et al., 2003). 50% of resulting progeny are expected to be 
heterozygous apcmcr/+ and 50% are expected to be wild type at the Apc locus 
(apc+/+). We scored liver size in the resulting RFP+ progeny and found 
approximately 50% had normal size livers and 50% had enlarged livers as 
previously reported (Goessling et al., 2008). Treatment with Torin1 or Rapamycin 
greatly reduced the percent of fish with enlarged livers and increased the percent 
with normal livers (Figure 3-4A,B). Genotyping confirmed strong correlation 
between heterozygous Apc mutation and liver enlargement in vehicle treated fish 
(Figure 3-4C,D). However, when Torin1 treated fish with normal size livers were 
genotyped, approximately half were found to be apcmcr/+, confirming that Torin1 
restores normal liver size in heterozygous Apc mutant zebrafish (Figure 3-4C,D). 
To quantify the effect of Torin1 treatment on liver hyperplasia, the number of 
RFP+ cells per liver was measured by flow cytometry. apcmcr/+ fish had 
approximately 75% more cells per liver and this was restored to wild type levels 
by Torin1 (Figure 3-4E). Torin1 had no effect on the number of hepatocytes in 
wild-type zebrafish. These data demonstrate a critical role for mTORC1 in liver 
hyperplasia resulting from oncogenic Apc mutation.  
 
3-3-5. Combined inhibition of mTORC1 and Wnt signaling reduces body 
curvature in apcmcr/mcr zebrafish  
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We have found that aberrant mTORC1 activation contributes to early 
lethality, reduced circulation, and liver hyperplasia resulting from oncogenic Apc 
mutation. Apc loss of function also activates Wnt/ß-catenin signaling, which plays 
a major role in Apc mutant phenotypes. Thus we asked whether combined 
inhibition of mTORC1 and Wnt/ß-catenin signaling could rescue additional 
phenotypes. Aberrant body curvature resulting from defects in morphogenesis of 
the anterior-posterior axis is one of the most prominent phenotypes in apcmcr/mcr 
zebrafish (Figure 3-5) (Hurlstone et al., 2003). Treatment with either Torin1 or the 
Wnt inhibitor XAV939 (Huang et al., 2009b) alone did not affect body curvature, 
but combining Torin1 and XAV939 resulted in apcmcr/mcr zebrafish with straight 
bodies similar to wild type (Figure 3-5A). Approximately 95% of vehicle, Torin1, 
or XAV939 treated apcmcr/mcr zebrafish had curved body axes, whereas 
approximately 40% of apcmcr/mcr zebrafish treated with Torin1 and XAV939 were 
straight (Figure 3-5B). Similarly, Rapamycin improved body curvature in 
combination with XAV939 but had no effect on its own (Figure 3-5C). 
Representative images of scoring categories used in panels B and C are show in 
panel D. These data highlight the importance of combined mTORC1 and Wnt/ß-
catenin signaling downstream of Apc mutation and demonstrate that 
simultaneous inhibition of both pathways can rescue Apc mutant phenotypes that 
are not rescued by targeting either pathway alone.  
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Figure 3-5 
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Figure 3-5. Combined inhibition of mTORC1 and Wnt signaling reduces 
body curvature in apcmcr/mcr zebrafish. (A) Representative images of apcmcr/mcr 
zebrafish at 2 dpf treated with vehicle, Torin1 (250nM), XAV939 (500nM), or 
Torin1 plus XAV939. Combined Torin1 and XAV939 treatment rescues body 
curvature whereas either treatment alone does not. (B) Zebrafish were scored 
between 2-3 dpf based on severity of body curvature and the percent of fish in 
each category is shown. Only combined Torin1 plus XAV939 treatment reduces 
body curvature. (C) Rapamycin also reduces body curvature in combination with 
XAV939, but not by itself. (D) Representative pictures of each of the three 
categories used to score body curvature in (B,C). 
 
 
 
 
 
 
 
 
 
 
 
 
	   91 
 
3-3-6. mTORC1 is strongly activated in Apcmin mouse intestinal polyps  
 
To confirm our findings in zebrafish using an established mammalian 
model of polyposis, we examined GSK-3 and mTORC1 activity in Apcmin mice, 
which develop intestinal adenomas through loss of heterozygosity (LOH) for Apc. 
Phospho-S6 staining was strongly induced in polyps compared to adjacent 
normal tissue (Figure 3-6A), similar to previous reports (Fujishita et al., 2008; 
Metcalfe et al., 2010). Furthermore, phosphorylation of glycogen synthase, an 
endogenous GSK-3 substrate, was markedly reduced in polyps, but not normal 
epithelium, from Apcmin mice (Figure 3-6B). These data are consistent with a 
model in which loss of APC reduces GSK-3 activity, which in turn activates both 
mTORC1 and Wnt/ß-catenin signaling. 
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Figure 3-6 
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Figure 3-6. mTORC1 is strongly activated and Glycogen Synthase 
phosphorylation is reduced in Apcmin mouse intestinal polyps. 
Immunostaining of intestinal sections from Apcmin mice. (A) Staining for 
phosphorylated S6, indicating mTORC1 activity, or total S6 reveals mTORC1 
activity is dramatically increased in polyps compared to immediately adjacent 
normal tissue. Asterisks indicate normal villi immediately adjacent to a polyp. (B) 
Immunostaining using an antibody to Glycogen Synthase phosphorylated at the 
GSK-3 phosphorylation site and counterstained with DAPI. Glycogen Synthase 
phosphorylation is strongly reduced in polyps compared to immediately adjacent 
normal intestine.  
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3-4. Discussion 
 
The importance of enhanced Wnt/ß-catenin activity as a mediator of Apc 
loss of function phenotypes is firmly established from studies in model organisms 
and in colorectal carcinomas in humans. However, reports that early neoplastic 
lesions may appear before nuclear localization of ß-catenin is detectable have 
prompted investigation into additional steps that may be required for the nuclear 
translocation and activation of ß-catenin (Phelps et al., 2009b; Rosenbluh et al., 
2012; Zhu et al., 2011). These reports have also raised the possibility that APC 
regulates additional effectors that contribute to Apc loss of function phenotypes. 
We show that truncating mutations in Apc, which are homologous to those found 
in human colorectal cancers and FAP, cause marked activation of mTORC1 and 
that mTORC1 activation contributes to Apc mutant phenotypes in zebrafish, 
including lethality in the larva stage, impaired circulation, defects in 
morphogenesis, and liver hyperplasia. Thus we identify widespread roles for 
aberrant mTORC1 activation in phenotypes resulting from oncogenic mutations 
in Apc.   
These findings are consistent with a signaling pathway in which APC 
directly enhances GSK-3 activity (Valvezan et al., 2012). We previously showed 
that APC directly facilitates GSK-3 activity in vitro and knockdown of APC 
reduces GSK-3 activity toward endogenous substrates, including glycogen 
synthase, in cultured cells. Inoki et al showed that GSK-3 suppresses mTORC1 
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activity (Inoki et al., 2006), and this was confirmed in vivo in mouse bone marrow 
(Huang et al., 2012; Huang et al., 2009a); thus our model predicts that inhibition 
of GSK-3 caused by Apc loss of function should activate mTORC1 in vivo. A 
number of findings here and in previous work strongly support this novel 
signaling module. Thus, we observe that GS phosphorylation is substantially 
reduced in intestinal polyps from Apcmin mice (Figure 3-6B). We also confirm that 
mTORC1 is markedly activated in Apc mutant polyps (Figure 3-6A), consistent 
with previous reports (Fujishita et al., 2008; Metcalfe et al., 2010). Furthermore, 
mTORC1 inhibitors reduce adenoma size and number, as well as mortality, in 
Apc mutant mice, demonstrating the importance of mTORC1 activation for 
tumorigenesis resulting from Apc mutation (Fujishita et al., 2008; Koehl et al., 
2010; Metcalfe et al., 2010). mTOR expression is also increased in Apc mutant 
polyps which may also contribute to elevated mTORC1 activity (Fujishita et al., 
2008). 
The importance of combined Wnt/ß-catenin and mTORC1 signaling in 
zebrafish development is also supported by our finding that aberrant body 
curvature in apcmcr/mcr zebrafish is rescued by combining mTORC1 inhibition with 
a Wnt pathway inhibitor, as neither inhibitor alone achieves rescue. We find that 
hyperplasia of the liver in heterozygous Apcmcr zebrafish is partially rescued by 
mTORC1 inhibition, and previous work demonstrated that this phenotype is also 
partially rescued by ß-catenin knockdown (Goessling et al., 2008), again 
indicating a role for both ß-catenin and mTORC1 in this hyperplastic phenotype. 
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Taken together, these data suggest activation of both mTORC1 and Wnt/ß-
catenin signaling contributes to multiple phenotypes resulting from oncogenic 
Apc mutation. 
In further support of a role for mTORC1 downstream of APC, Apcmcr 
zebrafish are partially phenocopied by knockdown of Tsc1, which causes similar 
defects in body curvature, and by genetic inactivation of Tsc2, which causes liver 
hyperplasia similar to Apcmcr heterozygotes (DiBella et al., 2009; Goessling et al., 
2008; Hurlstone et al., 2003; Kim et al., 2010). The Tsc2 phenotype is not 
identical to Apcmcr, however. This could be due to persistence of maternal Tsc2 
gene expression relative to Apc as well as the important role of ß-catenin and 
possibly other effectors downstream of APC.  
Extracolonic manifestations in FAP include polyps of the gastric fundus 
and small bowel, osteomas, lipomas, desmoid tumors, adrenal cortical 
adenomas, congenital hypertrophy of the retinal pigment epithelium (CHRPE) 
and hepatoblastomas (Rustgi, 2007), suggesting parallels with other hereditary 
disorders that cause neoplasias in multiple organs, including tuberous sclerosis, 
Peutz-Jeghers syndrome, and Cowden’s syndrome (Crino et al., 2006; Inoki et 
al., 2005; Rustgi, 2007). Peutz-Jeghers and Cowden’s syndromes are 
hamartomatous polyposis syndromes that involve multiple organ systems and 
are mediated in part through activation of mTORC1. Peutz-Jeghers syndrome is 
caused by mutations in LKB, an upstream regulator of AMPK and TSC2, and 
Cowden’s syndrome is caused by mutations in PTEN that also activate mTORC1 
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(Inoki et al., 2005). While each of these syndromes is clinically and pathologically 
distinct, it is interesting to note that they all share mTORC1 activation, which may 
be an early molecular step in tumor formation in each case. In contrast, the 
differences in these syndromes may be due to the fact that APC, LKB, and PTEN 
each regulate multiple other effectors.  
In conclusion, APC negatively regulates mTORC1 and oncogenic APC 
mutations disrupt this function, resulting in constitutive mTORC1 activation in 
both zebrafish and mammalian models. Several resulting phenotypes are 
partially rescued by mTORC1 inhibition, demonstrating a widespread role for 
mTORC1 activation downstream of APC mutation. Combined inhibition of 
mTORC1 and Wnt signaling rescues additional phenotypes, highlighting the 
importance of the unique combination of active mTORC1 and Wnt that results 
from oncogenic APC mutation. Combined inhibition of Wnt and mTORC1 
signaling may represent an effective strategy for treatment of colorectal cancers 
resulting from APC mutation. 
 
3-5. Materials and Methods 
 
3-5-1. Zebrafish  
 
Embryos were raised at 28.5oC in standard E3 medium (Westerfield, 
1993). 30µg/ml pronase (Roche #10165921001) was added at 24 hours post 
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fertilization (hpf) to digest the chorion and washed out at 48 hpf. Apcmcr zebrafish 
and primers used for genotyping were described previously (Hurlstone et al., 
2003). Lfabp:rfp zebrafish were described previously (Her et al., 2003). 
Rapamycin (LC Laboratories #R-5000), Torin1 (Tocris Bioscience #4247) and/or 
XAV939 (Sigma #X3004) were added directly into the fish medium starting at 24 
hpf unless otherwise indicated. Medium was changed and fresh treatments were 
added every 24 hours. Videomicroscopy and quantification of blood flow rate was 
performed in unanesthetized zebrafish larvae at 60 hpf as previously described 
(Hoage et al., 2012). Flow cytometry was performed as previously described 
(Goessling et al., 2008) except embryos were dissociated in 0.25% trypsin 
(Westerfield, 1993). For immunofluorescence, 3 dpf zebrafish embryos were 
fixed in 4% paraformaldehyde for 2 hours at room temperature, washed in PBST, 
dehydrated in an ascending ethanol series and submitted to the Perelman 
School of Medicine Cancer Histology Core at the University of Pennsylvania for 
paraffin embedding and sectioning. Immunofluorescence staining for S6 and 
phospho-S6 was performed as in Apcmin mouse intestinal sections (see below). 
Zebrafish husbandry and egg procurement were carried out in accordance with 
the guidelines of the University of Pennsylvania Institutional Animal Care and 
Use Committee. 
 
3-5-2. Lysis and western blots  
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Zebrafish embryos were lysed on ice in 5µl/embryo of buffer containing 
1% NP-40, 20mM Tris pH  8.0, 50mM NaCl, 2.5mM EDTA, 1mM DTT, protease 
inhibitor cocktail (Sigma #P8340) diluted 1:100, phosphatase inhibitor cocktails 
#2 (Sigma #P5726) and #3 (Sigma #P0044) also diluted 1:100 each. Equal 
volume of standard 2X Laemmli Sample Buffer was added and samples were 
heated at 95oC for 5 minutes and then centrifuged at 14,000 rpm for 5 minutes at 
4oC. Supernatants were collected for SDS-PAGE and western blot analysis using 
the following antibodies purchased from Cell Signaling Technology: S6 ribosomal 
protein (#2317), phospho-S6 ribosomal protein Ser235/236 (#4858).   
 
3-5-3. Apcmin mice  
 
Apcmin mice were purchased from The Jackson Laboratory (stock 
#002020) and described previously (Moser et al., 1993). For 
immunofluorescence, intestines were fixed in 10% phosphate buffered formalin 
overnight, washed in PBST, dehydrated in an ascending ethanol series and 
submitted to the Perelman School of Medicine Molecular Pathology and Imaging 
Core at the University of Pennsylvania for paraffin embedding and sectioning. 
Paraffin embedded sections were washed in xylene and rehydrated in a 
descending ethanol series followed by boiling in 10mM sodium citrate pH 6.0 and 
blocking in Starting Block buffer (Thermo Scientific #37539). Antibodies to S6, 
phospho-S6 Ser235/236, or phospho-Glycogen Synthase Ser641 (Cell Signaling 
	   100 
 
Technology #3891) were added overnight at 4oC followed by incubation with Cy2 
or Cy3 conjugated secondary antibodies.  
 
3-6. Supplemental Video Legends 
 
Online Supplemental Video 3-1. Wild type circulation. Representative video 
showing circulation through the dorsal aorta of a wild type zebrafish at 
approximately 60 hpf. Circulation is rapid (mean flow rate > 0.4 mm/sec) and 
pulsatile. 
 
Online Supplemental Video 3-2. Slightly reduced circulation. Representative 
video showing circulation through the dorsal aorta of an apcmcr/mcr zebrafish 
scored as “Slightly reduced” in Figure 3 at approximately 60 hpf. Mean flow for 
this group was 0.2- 0.4 mm/sec and was still pulsatile. 
 
Online Supplemental Video 3-3. Severely reduced circulation. 
Representative video showing circulation through the dorsal aorta of an apcmcr/mcr 
zebrafish scored as “Severely reduced” in Figure 3 at approximately 60 hpf. This 
category was defined as mean flow rate of 0-0.2 mm/sec. 
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Online Supplemental Video 3-4. No Circulation. Representative video showing 
lack of circulation through the dorsal aorta of an apcmcr/mcr zebrafish scored as 
having “No circulation” in Figure 3 at approximately 60 hpf. No circulating cells 
are visible.  
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
4-1. Overview 
 
 The Wnt pathway is essential for patterning and cell fate specification 
during embryogenesis and for tissue maintenance and regeneration in adults. 
Aberrant Wnt activation is critical for development and progression of many 
cancers. APC is an essential negative regulator of the Wnt pathway and 
mutations in Apc potently induce tumorigenesis. The mechanistic role of APC in 
the Wnt pathway and the downstream effectors of oncogenic Apc mutations are 
not known. APC promotes β-catenin phosphorylation by GSK-3 and has similar 
roles as GSK-3 in various cellular processes including mitotic spindle formation, 
cell migration, and axon specification. Furthermore, APC and GSK-3 loss of 
function phenocopy one another during development of many organs and 
tissues, and in stem cell regulation in adults. Thus we asked if APC can regulate 
GSK-3 and GSK-3 dependent signaling. To address this question we examined 
the effects of APC on GSK-3 activity in vitro, and the effects of APC loss of 
function on substrates and signaling pathways regulated by GSK-3 in human 
cells, mice, and zebrafish. We find APC directly enhances GSK-3 activity and 
thus regulates GSK-3 dependent signaling, including signaling through Glycogen 
Synthase (GS) and mTORC1. Our findings uncover new roles for APC and 
suggest a widespread role for APC in regulating GSK-3 dependent signaling. We 
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also find that Wnts induce APC dissociation from the GSK-3/Axin complex, 
suggesting a novel mechanism for how Wnts regulate GSK-3 activity.  
 We examined the effects of oncogenic Apc mutations on mTORC1 and 
find that these mutations activate mTORC1 which contributes to many resulting 
phenotypes. These data suggest a new model for colorectal cancer pathogenesis 
in which Apc mutations reduce GSK-3 activity, resulting in combined activation of 
Wnt/β-catenin and mTORC1 signaling.  
 Our work raises many intriguing questions, some of which will be 
discussed in this chapter. These questions include: How does APC enhance 
GSK-3 activity? How does APC regulate mTORC1? Does APC play widespread 
roles in GSK-3 dependent signaling and regulation of GSK-3 substrates? Do 
APC and GSK-3 interact independently of Axin? Is APC dissociation from Axin 
required for Wnt signal transduction? Does APC regulate embryonic 
development and stem cell homeostasis through GSK-3 and mTORC1? Is 
mTORC1 activation required for tumorigenesis downstream of Apc mutation? 
Finally, can combined inhibition of mTORC1 and Wnt/β-catenin signaling 
effectively treat colorectal cancer?  
  
4-2. APC regulates GSK-3 activity and GSK-3 dependent signaling 
 
We examined a role for APC in regulation of GSK-3 activity and found that 
APC enhances phosphorylation of tau and β-catenin by GSK-3. Surprisingly, this 
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occurs even in the absence of the Axin scaffold, suggesting APC directly 
interacts with and enhances GSK-3 activity. Future work is needed to elucidate 
the mechanism by which APC enhances GSK-3 activity. APC may induce 
conformational changes or stabilize active GSK-3 conformations. To explore this 
possibility, the crystal structure of GSK-3 can be examined and compared in the 
presence and absence of APC. Alternatively, APC may promote interaction 
between GSK-3 and its substrates. APC can directly bind β-catenin, but direct 
APC interaction with tau has not been reported. To test this possibility, we can 
disrupt the β-catenin binding sites on APC and see if it can still enhance β-
catenin phosphorylation by GSK-3. We can also identify regions of APC that are 
required to enhance GSK-3 activity to provide insight into how it performs this 
function. This can be achieved through deletion analysis followed by in vitro 
kinase assays for GSK-3 activity in the presence or absence of APC fragments. 
An interesting potential candidate region is the recently described β-catenin 
inhibitory domain (CID) of APC. This region spans approximately 60 amino acids 
and is required for APC to downregulate β-catenin, but its mechanism of action is 
unknown (Kohler et al., 2009). It is located between two β-catenin binding sites 
and has no known interacting partners. The CID is included in the SAMP 
fragment of APC used in our in vitro assays, and could contribute to enhancing 
GSK-3 activity. APC also binds topoisomerase IIα and enhances its enzymatic 
activity (Wang et al., 2008), and binds the Rac1 and Cdc42 specific guanine 
nucleotide exchange factor Asef1 and enhances its GEF activity (Kawasaki et al., 
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2000). Taken together, these data suggest APC directly enhances GSK-3 activity 
and may have a broader role in regulating enzymatic activity. There is little 
overlap between the APC fragment that enhances topoisomerase IIα activity and 
the SAMP fragment that enhances GSK-3 activity, and there is no overlap 
between either of these two fragments and the fragment that enhances Asef1 
activity, suggesting APC may regulate activity of these enzymes through distinct 
domains. 
Our finding that APC can enhance GSK-3 activity led us to ask whether 
APC regulates other GSK-3 substrates or GSK-3 dependent signaling pathways. 
APC is an essential negative regulator of Wnt signaling, and we find additional 
roles for APC as an essential negative regulator of GS and mTORC1. APC 
knockdown reduces inhibitory phosphorylation of GS by GSK-3 without activating 
upstream PI3K/Akt signaling, consistent with direct regulation of GSK-3 by APC. 
APC knockdown also mimics GSK-3 inhibition by activating mTORC1. 
Furthermore, mTORC1 is aberrantly active in many tissues in Apc mutant 
zebrafish, and we find reduced GS phosphorylation and aberrant mTORC1 
activation in intestinal adenomas in Apc mutant mice. Importantly, activating 
downstream Wnt signaling by expressing constitutively active β-catenin does not 
affect GS or mTORC1 activity. These data identify novel roles for APC in the 
regulation of GS and mTORC1, and suggest APC regulation of GSK-3 activity is 
important in several signaling pathways.  
Surprisingly, we observe strong mTORC1 activation in whole embryo 
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lysates from apcmcr/mcr zebrafish compared to pooled wild type and heterozygous 
mutants by western blot analysis (Figure 3-1). Immunohistochemical staining 
also confirms nearly global mTORC1 activation in apcmcr/mcr zebrafish (Figure 3-
1). mTORC1 integrates many upstream signals that control its activity, and how 
decisions are made in the presence of competing signals is an area of intense 
investigation. Our observations suggest that inhibitory input from APC and GSK-
3 may be required to inactivate mTORC1 even in the presence of other inhibitory 
signals. However it is also possible that APC regulates several factors that 
influence mTORC1, such as Akt or ERK. We find APC knockdown activates 
mTORC1 without affecting Akt phosphorylation or GSK-3 phosphorylation by Akt, 
suggesting APC does not regulate Akt activity (Figure 2-1). 
Future work should continue to address the mechanism by which APC 
inhibits mTORC1. APC enhances GSK-3 activity and GSK-3 inhibits mTORC1 by 
phosphorylating TSC2 (Inoki et al., 2006). Thus we can determine whether APC 
loss of function reduces TSC2 phosphorylation by GSK-3. In contrast to our 
model, APC may not promote TSC2 phosphorylation by GSK-3, and could 
regulate mTORC1 through a different mechanism. This would prompt 
investigation into whether APC regulates other upstream factors that control 
mTORC1 activity, including ERK and AMPK. APC loss of function activates ERK 
(discussed further on pgs 107-108), and ERK activates mTORC1. Thus we could 
ask if ERK inhibition blocks mTORC1 activation. 
APC may also regulate other GSK-3 dependent signaling pathways 
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through its ability to enhance GSK-3 activity. Bone morphogenetic protein (BMP) 
signaling promotes phosphorylation of receptor regulated Smads (R-Smads) 
which allows them to bind Smad4 and translocate to the nucleus to activate 
transcription (ten Dijke, 2006). GSK-3 phosphorylates R-Smads at different sites 
which promote R-Smad degradation. GSK-3 inhibition enhances the magnitude 
of BMP target gene and BMP reporter activation in response to BMP ligands, as 
well as the duration of the response (Fuentealba et al., 2007; Fukuda et al., 
2010). Interestingly, APC knockdown similarly increases activation of a BMP 
reporter by BMP ligands (Miclea et al., 2011). Expression of stabilized, 
constitutively active β-catenin has no effect on BMP signaling (Fuentealba et al., 
2007; Fukuda et al., 2010). These data suggest that both APC and GSK-3 
negatively regulate BMP signaling in a β-catenin-independent manner. Future 
work is needed to determine whether APC promotes R-Smad phosphorylation by 
GSK-3. 
GSK-3 also regulates signaling through extracellular signal-related kinase 
(ERK). Extracellular signals such as EGF activate RAS and induce activating 
phosphorylation of MEK which subsequently phosphorylates and activates ERK. 
GSK-3 knockdown increases ERK phosphorylation and expression of 
downstream targets of ERK activation (Wang et al., 2006; Zhai et al., 2007). 
Furthermore, treatment with GSK-3 inhibitors increases ERK phosphorylation 
within 30 minutes (Wang et al., 2006). These data suggest GSK-3 negatively 
regulates ERK activity. Similarly, ERK phosphorylation is induced by loss of APC 
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function, and expressing wild type APC decreases ERK phosphorylation in Apc 
mutant colorectal cancer cells. APC overexpression also blocks RAS-induced 
cell proliferation (Park et al., 2006). The mechanism by which GSK-3 regulates 
ERK is not clear, but may involve GSK-3 phosphorylating and stabilizing mitogen 
kinase phosphatase-1 (MKP-1) which de-phosphorylates and thus deactivates 
MEK (Wang et al., 2009b). Thus we can ask whether APC promotes MKP-1 
phosphorylation by GSK-3.  
APC has also been shown to promote phosphorylation of direct GSK-3 
substrates. For example, APC promotes β-catenin and GS phosphorylation by 
GSK-3. GSK-3 phosphorylates the transcription factor CCAAT enhancer-binding 
protein β (C/EBPβ) (Zhao et al., 2005), and APC knockdown reduces C/EBPβ 
phosphorylation at the GSK-3 sites (Larabee et al., 2011). These data suggest 
APC also promotes C/EBPβ phosphorylation by GSK-3. Bacillus anthracis 
edema toxin (ET) activates GSK-3 in the nucleus, and GSK-3 inhibitors block 
effects of ET on gene expression and cell cycle progression (Larabee et al., 
2008). Interestingly, ET increases levels of nuclear APC and promotes physical 
interaction between APC, GSK-3, and C/EBPβ in the nucleus. Apc knockdown or 
mutation also blocks effects of ET on gene expression, as does C/EBPβ 
knockdown (Larabee et al., 2011). These data suggest ET promotes nuclear 
association between APC and GSK-3 to promote C/EBPβ phosphorylation by 
GSK-3.  
Taken together, these data suggest APC promotes phosphorylation of β-
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catenin, GS, and C/EBPβ by GSK-3, and negatively regulates Wnt, mTORC1, 
BMP, and ERK signaling, like GSK-3. APC negatively regulates Wnt signaling by 
promoting phosphorylation of β-catenin by GSK-3. APC may regulate mTORC1, 
BMP, and ERK signaling by promoting phosphorylation of TSC2, R-Smads, and 
MKP-1 respectively by GSK-3 (Table 4-1).  
Future work is also needed to determine whether APC regulates additional 
GSK-3 substrates and GSK-3 dependent signaling pathways. GSK-3 inhibits 
Notch signaling by phosphorylating and destabilizing the Notch intracellular 
domain (NICD) (Jin et al., 2009; Kim et al., 2009), and Hedgehog signaling by 
phosphorylating Ci/Gli to promote its proteolytic processing to generate a 
truncated repressor (Forde and Dale, 2007; Jia et al., 2002; Price and Kalderon, 
2002). The role of APC in Notch and Hedgehog signaling or phosphorylation of 
NICD or Ci/Gli has not been examined. GSK-3 also phosphorylates over 100 
putative substrates and a role for APC in regulating the vast majority of them has 
not been examined. Future work could determine whether APC loss of function 
reduces NICD and Ci/Gli phosphorylation by GSK-3, and activates Notch and 
Hedgehog target genes. We can also survey many GSK-3 substrates to see 
which are affected by APC loss of function. Phosphorylation-specific antibodies 
are available to detect phosphorylation of many GSK-3 substrates including p53, 
c-Myc, amyloid precursor protein, and cyclin E. Thus we can knockdown APC 
expression in cultured cells or induce Apc deletion in mice and western blot or 
immunostain to detect phosphorylation of GSK-3 substrates.  
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Table 4-1  
Signaling 
pathway 
GSK-3 function APC function 
   
Wnt - Inhibits Wnt signaling  
 
- Phosphorylates β-catenin 
 
- Inhibits Wnt signaling 
 
- Promotes β-catenin 
phosphorylation 
 
Insulin/Glycogen 
Synthase 
- Phosphorylates Glycogen 
Synthase 
- Promotes Glycogen Synthase 
phosphorylation 
mTORC1 - Inhibits mTORC1 
 
- Phosphorylates TSC2 
 
- Inhibits mTORC1 
 
 
BMP - Inhibits BMP signaling 
 
- Phosphorylates R-Smads 
 
- Inhibits BMP signaling 
 
 
 
ERK 
 
- Inhibits ERK 
 
- Inhibits ERK 
 
C/EBPβ 
 
- Phosphorylates C/EBPβ 
 
- Promotes C/EBPβ 
phosphorylation 
 
Table 4-1. GSK-3 and APC play similar roles in many signaling pathways. 
GSK-3 is an essential negative regulator of diverse signaling pathways. APC 
inhibits many of the same signaling pathways by promoting phosphorylation of 
GSK-3 substrates.  
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4-3. Axin-independent APC/GSK-3 interaction 
 
APC and GSK-3 physically associate through the scaffolding protein Axin 
which mediates β-catenin phosphorylation by GSK-3. GSK-3 suppresses 
mTORC1 activity by phosphorylating TSC2 which also associates with Axin 
(Inoki et al., 2006; Mak et al., 2005). Wnt signaling inhibits GSK-3 in the Axin 
complex, reduces TSC2 phosphorylation, and activates mTORC1 within minutes 
(Inoki et al., 2006; MacDonald et al., 2009). Axin knockdown also activates 
mTORC1 (Inoki et al., 2006, Supplemental Figure S2-6B). These data suggest 
TSC2 and mTORC1, like β-catenin, are regulated by GSK-3 in the Axin complex. 
To confirm this, additional experiment should test whether disrupting Axin/GSK-3 
or Axin/TSC2 interaction reduces TSC2 phosphorylation and activates mTORC1.  
APC and GSK-3 also negatively regulate BMP and ERK signaling 
(Fuentealba et al., 2007; Fukuda et al., 2010; Miclea et al., 2011; Park et al., 
2006; Wang et al., 2006; Zhai et al., 2007). Treatment with Wnt ligands for 1 hour 
reduces R-Smad phosphorylation by GSK-3 and increases total R-Smad levels 
(Fuentealba et al., 2007). GSK-3 regulates ERK signaling by antagonizing 
phosphorylation of MEK and ERK. Wnt ligands induce phosphorylation of MEK 
and ERK within 30 minutes (Yun et al., 2005) and Axin knockdown similarly 
increases MEK and ERK phosphorylation (Jeon et al., 2007). Axin 
overexpression reduces MEK and ERK phosphorylation and blocks EGF induced 
reporter activation and EGF induced cell proliferation (Jeon et al., 2007). These 
	   112 
 
data suggest BMP and ERK signaling may also be regulated by GSK-3 and APC 
in the Axin complex.  
GSK-3 also phosphorylates and inhibits Glycogen Synthase, but Wnt 
signaling and Axin knockdown do not affect GS phosphorylation (Supplemental 
Figure S2-6). As APC promotes GS phosphorylation by GSK-3 (Figure 2-1), 
these data suggest a functional Axin-independent APC/GSK-3 interaction and 
raise the question of whether APC and GSK-3 can physically associate in an 
Axin-independent manner.  
Stable Axin-independent APC/GSK-3 association has not been reported to 
date. GSK-3 phosphorylates APC at multiple sites (Ikeda et al., 2000; Rubinfeld 
et al., 1996; Zumbrunn et al., 2001), and APC directly enhances GSK-3 activity in 
vitro (Figure 2-3), suggesting APC and GSK-3 can directly interact. However, 
stable direct APC/GSK-3 binding is not detected in vitro (Hinoi et al., 2000), and 
scaffolding proteins may be required for them to function together in cells. In 
support of this, APC and GSK-3 must each interact directly with the Axin scaffold 
for β-catenin to be efficiently phosphorylated by GSK-3 in cells. Cell fractionation 
studies indicate APC exists in at least two distinct cytoplasmic complexes, one of 
which was identified as the Axin/β-catenin destruction complex (Penman et al., 
2005). The function of the other complex, and whether it contains GSK-3 have 
not been determined (Penman et al. proposed this complex interacts with and 
regulates microtubules based on the ability of APC in those fractions to bind 
microtubules in vitro (Penman et al., 2005)).  
	   113 
 
Additional experiments are needed to determine whether APC and GSK-3 
stably interact in the absence of Axin. For example, APC can be 
immunoprecipitated from SNU475 cells which do not express Axin (Satoh et al., 
2000), to see if GSK-3 is associated, and vice versa. Common interacting 
partners between APC and GSK-3 can also be identified to provide insight into 
potential scaffolding proteins and complexes that might bind both APC and GSK-
3. If another scaffold or complex that binds both APC and GSK-3 is identified, we 
can ask whether deletion of the scaffold, or of proteins essential for complex 
formation, reduces GS phosphorylation by GSK-3. We can also test whether 
specific removal of APC or GSK-3 from the complex reduces GS 
phosphorylation.  
 
4-4. Wnt signaling induces APC dissociation from the Axin complex 
 
 Wnt signaling inhibits GSK-3 through an unknown mechanism to stabilize 
β-catenin and activate downstream signaling. APC enhances GSK-3 activity and 
direct APC/Axin interaction is required to downregulate β-catenin and inhibit Wnt 
signaling. These data led us to hypothesize that Wnts disrupt APC interaction 
with Axin to reduce GSK-3 activity and stabilize β-catenin. We find Wnts rapidly 
induce APC dissociation from Axin without affecting GSK-3/Axin interaction. 
Consistent with our hypothesis, APC dissociation correlates closely with β-
catenin stabilization. Wnt signaling recruits Axin to LRP6 at the plasma 
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membrane and we find Axin interaction with LRP6 causes APC dissociation. 
These data suggest Wnt-induced Axin recruitment to LRP6 promotes APC 
dissociation to reduce GSK-3 activity and activate downstream signaling.  
 Consistent with our model, Axin, LRP6, GSK-3, β-catenin, and the Axin 
binding protein microtubule actin cross-linking factor-1 (MACF-1), but not APC, 
are detected in isolated cell membranes following Wnt stimulation. Furthermore, 
MACF-1 immunoprecipitation from membrane fractions after Wnt stimulation 
reveals MACF-1 interaction with Axin, LRP6, GSK-3, and β-catenin, but not APC 
(Chen et al., 2006).  
Tran and Polakis show that APC within the Axin complex is 
polyubiquitinated on lysine 63 (Tran and Polakis, 2012). Knocking down HectD1, 
the E3 ubiquitin ligase that polyubiquitinates APC on K63, disrupts APC/Axin 
interaction (Tran et al., 2013). Interestingly, Wnts reduce K63 polyubiquitination, 
correlating with APC dissociation and β-catenin stabilization (Tran and Polakis 
also immunoprecipitated APC and found that Wnts reduce the amount of 
associated Axin, thus reproducing our finding that Wnts induce APC dissociation 
from the Axin complex) (Tran and Polakis, 2012). Taken together, these data 
suggest Wnts induce APC dissociation from the Axin complex, possibly by 
reducing polyubiquitination at lysine 63 within APC.  
While we demonstrate that Wnt signaling induces APC dissociation from 
Axin which correlates with β-catenin stabilization, additional experiments are 
needed to determine whether APC dissociation is required for, or contributes to, 
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β-catenin stabilization. To prevent APC dissociation, an Axin-APC fusion protein 
can be expressed and the rate of β-catenin accumulation in response to Wnt 
ligands can be measured. Alternatively, previously described inducible 
dimerization systems (Bayle et al., 2006) can be employed to force APC 
interaction with Axin in the presence of Wnt ligands. The Axin complex can also 
be immunoprecipitated followed by in vitro kinase assay to determine whether 
APC dissociation from Axin contributes to reduced GSK-3 activity. We find Axin 
binding to LRP6 causes APC dissociation. To test whether Axin binding to LRP6 
reduces K63 polyubiquitination, we can express a constitutively active LRP6 
fragment that binds Axin, or control fragment that does not bind Axin (Figure 2-5) 
to see if they affect K63 polyubiquitination. Deubiquitylating enzymes can also be 
screened to identify ones that are required for Wnt-induced deubiquitination of 
APC. We can then determine whether those enzymes are required for Wnt-
induced APC dissociation.  
 APC binds directly to the regulator of G-protein signaling (RGS) domain of 
Axin. G Protein-Coupled Receptor Kinase 2 (GRK2) contains a similar RGS 
domain which also directly binds APC. Interestingly, Wnt signaling enhances 
interaction between APC and the RGS domain of GRK2 (Wang et al., 2009a). 
These data suggest Wnts may induce APC dissociation from Axin allowing 
association with GRK2 instead. The functional significance of APC interaction 
with GRK2 is not known. To address this, future experiments can determine 
whether deletion of the RGS domain of GRK2 affects β-catenin stabilization or 
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activation of Wnt target genes.  
 APC enhances β-catenin phosphorylation by GSK-3 within the Axin 
complex, but also reduces β-catenin dephosphorylation by protein phosphatase 
2A (PP2A). PP2A binds directly to Axin and is a component of the Axin/GSK-
3/APC/β-catenin complex. β-catenin is rapidly dephosphorylated by PP2A in Apc 
mutant colorectal cancer cell extracts, and this is blocked by the addition of wild 
type APC. Similarly, APC blocks dephosphorylation of β-catenin by PP2A when 
purified proteins are assayed in vitro (in the absence of cell extracts) (Su et al., 
2008). Thus APC prevents β-catenin dephosphorylation by PP2A. These data 
suggest Wnt-induced APC dissociation from the Axin complex reduces β-catenin 
phosphorylation by both reducing GSK-3 activity and allowing β-catenin 
dephosphorylation by PP2A. This parallels other signaling pathways in which 
reduced phosphorylation of an essential effector is achieved rapidly by 
simultaneous inhibition of the predominant kinase and activation of a 
phosphatase. For example, insulin activates Akt which phosphorylates and 
inhibits GSK-3 so it can no longer phosphorylate GS. Insulin also activates 
glycogen targeted protein phosphatase-1 which dephosphorylates GS (Brady 
and Saltiel, 2001).  
  
4-5. Roles for APC through regulation of GSK-3 and mTORC1  
 
GSK-3 suppresses mTORC1 activity (Inoki et al., 2006). We find APC 
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enhances GSK-3 activity and negatively regulates mTORC1. These observations 
led us to ask whether APC regulation of GSK-3 and mTORC1 is important during 
embryonic development. mTORC1 is aberrantly activate in apcmcr/mcr zebrafish 
and we hypothesized that mTORC1 contributes to Apc mutant phenotypes. We 
find mTORC1 inhibition extends the survival of apcmcr/mcr zebrafish and partially 
rescues circulation defects. mTORC1 inhibition also rescues liver enlargement in 
heterozygous apcmcr  zebrafish, and rescues defects in morphogenesis of the 
anterior-posterior axis when combined with a Wnt inhibitor in homozygous 
mutants. These data suggest mTORC1 activation contributes to Apc mutant 
phenotypes, and highlight the importance of APC suppressing mTORC1 activity 
during development.   
Early lethality in apcmcr/mcr zebrafish is likely the result of heart defects 
which include hyperproliferation of the endocardial cushions. Endocardial 
cushions in these fish do not form a proper valve and instead proliferate and 
eventually fuse, separating the ventricle from the atrium and blocking circulation 
(Hurlstone et al., 2003). We find mTORC1 inhibition improves circulation and 
extends the survival of apcmcr/mcr zebrafish, suggesting mTORC1 activation may 
contribute to cushion hyperproliferation and reduced cardiac function. However, 
circulation is an indirect measure of heart function and survival may be 
influenced by other factors. Therefore additional experiments are needed to 
directly address the role of APC and the effects of aberrant mTORC1 activation 
on heart development. Immunohistochemical staining for phosphorylated S6 can 
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be performed to determine whether mTORC1 is aberrantly active in the heart and 
more specifically, in the endocardial cushions in apcmcr/mcr zebrafish. IHC and in 
situ hybridization can also be used to see if mTORC1 inhibition reduces valve 
markers and proliferative markers which are upregulated in apcmcr/mcr zebrafish. In 
vivo imaging and high speed videomicroscopy can also be utilized to assess 
whether mTORC1 inhibition reduces cushion proliferation or rescues heart valve 
formation. Contractility and blood flow through the heart can be measured to see 
if mTORC1 inhibition improves cardiac function.  
Wnt ligands are expressed in endocardial cushions and developing 
atrioventricular valves in mice, and a Wnt/β-catenin reporter is active in these 
tissues (Alfieri et al., 2009). Wnt/β-catenin signaling is also active in endocardial 
cushions in zebrafish. The Wnt inhibitor Dkk1 blocks cushion formation in 
zebrafish, indicating Wnt signaling plays a critical role in cushion and valve 
formation (Hurlstone et al., 2003). Cushion-specific overexpression of Wnt 
ligands in chick embryos also causes cushion hyperproliferation that blocks AV 
blood flow (Person et al., 2005). These data suggest aberrant β-catenin signaling 
in apcmcr/mcr zebrafish could contribute to the cushion and valve defects. 
Importantly, these data do not conclusively demonstrate a role for β-catenin, 
since Wnt signaling also activates mTORC1 (Inoki et al., 2006).  
GSK-3β knockdown also results in hyperproliferation of endocardial 
cushions and failure to form a functional heart valve (Lee et al., 2007), as does a 
mutation in Axin (mbl) that disrupts its interaction with GSK-3 (Heisenberg et al., 
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2001; Hurlstone et al., 2003). apcmcr/mcr zebrafish hearts also fail to loop, and this 
is phenocopied by GSK-3β knockdown or Axin mbl mutation (Heisenberg et al., 
2001; Hurlstone et al., 2003; Lee et al., 2007). Taken together, these data 
suggest a critical role for APC in regulating cardiac development by activating 
GSK-3 in the Axin complex and inhibiting β-catenin and mTORC1.  
Wnt/β-catenin signaling is essential during many stages of heart 
development and is required for heart looping and formation of functional AV 
valves (Brade et al., 2006). However, β-catenin overexpression has not been 
shown to be sufficient to cause heart looping or valve defects. This could simply 
be because β-catenin has not been overexpressed in the endocardial cushions 
when they are proliferating to form the valves. β-catenin overexpression early 
during development induces an ectopic secondary axis, and later suppresses 
anterior development and can block heart formation (Ciani and Salinas, 2005; 
Kelly et al., 1995; Ueno et al., 2007). The presence of maternal wild type APC 
likely prevents these early Wnt activation phenotypes in apcmcr/mcr zebrafish. 
Alternatively, the lack of heart looping or heart valve defects in response to β-
catenin overexpression could indicate that activation of both β-catenin and 
mTORC1 signaling is important in apcmcr/mcr zebrafish, GSK-3β morphants and 
Axin mbl mutants (and/or disruption of other overlapping functions of APC, GSK-
3, and Axin). Similarly, TSC loss of function activates mTORC1 and mimics some 
Apc mutant phenotypes, but heart looping or heart valve defects have not been 
reported (DiBella et al., 2009; Kim et al., 2010).   
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To assess the relative contributions of Wnt/β-catenin and mTORC1 
signaling to heart defects in apcmcr/mcr zebrafish, Wnt/β-catenin signaling can be 
inhibited alone and in combination with mTORC1 inhibition. Heart looping, 
endocardial cushion proliferation, valve formation, and cardiac function can be 
assessed using the techniques described earlier (pg 118). Transgenic zebrafish 
can also be made to express constitutively active β-catenin in the developing 
heart tube or endocardial cushions to see if β-catenin activation is sufficient to 
induce the heart defects seen in apcmcr/mcr zebrafish. Transgenic zebrafish can 
also be created to allow inducible TSC deletion, and thus mTORC1 activation, in 
the developing heart to see if mTORC1 activation phenocopies heart defects in 
apcmcr/mcr zebrafish. To provide evidence that Apc mutant phenotypes result from 
reduced GSK-3 activity, we can overexpress GSK-3 in apcmcr/mcr zebrafish to see 
if it rescues heart defects. Furthermore, if a region of APC that is essential for 
enhancing GSK-3 activity can be identified (as proposed in section 4-2, pg 104), 
we can see if expressing an APC mutant that lacks this region rescues apcmcr/mcr 
zebrafish. Rescue by wild type APC and not the APC mutant would suggest a 
requirement for APC enhancing GSK-3 activity.   
Preliminary observations suggest combining the Wnt inhibitor XAV939 
with mTOR inhibitors does not fully rescue heart looping defects in apcmcr/mcr 
zebrafish (although more thorough dose curves and treatment time courses are 
needed). These observations raise the possibility that additional functions of APC 
may contribute. For example, BMP signaling is active on one side on the 
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developing heart tube, establishing early asymmetry that is required for heart 
looping. Thus inhibition or ectopic activation of BMP signaling in the heart tube 
prevents looping (Breckenridge et al., 2001; Chen et al., 1997). APC and GSK-3 
negatively regulate BMP signaling (Fuentealba et al., 2007; Fukuda et al., 2010; 
Miclea et al., 2011). These data suggest BMP signaling may be ectopically active 
in apcmcr/mcr zebrafish which contributes to failed heart looping. 
APC regulation of GSK-3 and mTORC1 may also be critical during liver 
development. Heterozygous apcmcr/+ zebrafish develop enlarged, hyperplastic 
livers, which can be rescued by mTORC1 inhibition (Figure 3-4). β-catenin 
signaling is active in apcmcr/+ livers and β-catenin knockdown also rescues liver 
enlargement. Apoptosis during liver development in apcmcr/mcr zebrafish results in 
failure to form a morphologically identifiable liver (Goessling et al., 2008). 
Similarly, Apc deletion in murine hepatoblasts causes liver degeneration and 
lethality (Decaens et al., 2008). Significant apoptosis is also observed in the 
livers of Gsk-3β knockout mice, resulting in liver degeneration and lethality 
around the same time as the hepatoblast-specific Apc mutants (Hoeflich et al., 
2000). Tsc2 null mice also die around the same time from severe liver hypoplasia 
(Onda et al., 1999). Taken together, these data suggest repression of mTORC1 
and β-catenin by APC is essential for liver development and control of liver size. 
Immunohistochemical staining for phosphorylated S6 should be performed in the 
future to see if mTORC1 is aberrantly active in Apc and Gsk-3β mutant livers. 
These fish and mice can also be treated with Wnt and mTOR inhibitors alone or 
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in combination to see if they block liver apoptosis and rescue liver development.  
APC regulation of GSK-3 and mTORC1 may also be essential for 
development of other organs and tissues, and for stem cell regulation in adults. 
As examples, abnormal body curvature in apcmcr/mcr zebrafish is rescued by 
combined mTORC1 and Wnt/β-catenin inhibition, suggesting suppression of both 
of these signaling pathways by APC is essential for morphogenesis of the 
anterior-posterior axis. GSK-3 knockdown in mouse bone marrow causes short 
term expansion of hematopoietic stem cells (HSCs), which requires β-catenin, 
and long term depletion which is caused by mTORC1 activation (Huang et al., 
2009). Conditional APC deletion in mouse bone marrow similarly causes short 
term HSC expansion and long term depletion (Qian et al., 2008). These data in 
combination with our observations suggest widespread roles for APC through 
regulation of GSK-3 and mTORC1.   
 
4-6. Apc mutations promote tumorigenesis through combined Wnt and 
mTORC1 activation  
 
  APC is a tumor suppressor that is mutated in most colorectal cancers. 
Apcmcr zebrafish contain a premature stop codon within the mutation cluster 
region of Apc, resulting in expression of a truncated protein analogous to those 
commonly found in human colorectal cancers (Hurlstone et al., 2003). 
Heterozygous Apcmcr/+ zebrafish develop adenomas in multiple tissues, including 
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the intestine (Haramis et al., 2006). We find mTORC1 is aberrantly active in 
Apcmcr zebrafish, and mTORC1 contributes to many development defects in 
these fish. We hypothesize that oncogenic Apc mutations reduce GSK-3 activity 
and activate Wnt and mTORC1 which combine to strongly promote 
tumorigenesis. In support of this, we find reduced GS phosphorylation and active 
mTORC1 in adenomas in Apcmin mice. Furthermore, we find mTORC1 is 
constitutively active in Apc mutant colorectal cancer cells and can be turned off 
by reintroduction of wild type APC.  
Reduced GS phosphorylation in intestinal adenomas in Apcmin mice could 
be due to additional mutations. Therefore future work should address the effects 
of truncating Apc mutations on GSK-3 activity in more detail. To provide further 
evidence that truncating Apc mutations reduce GSK-3 activity, we can examine 
phosphorylation of multiple GSK-3 substrates in wild type compared to apcmcr/mcr 
zebrafish, or in Apc mutant intestinal adenomas. GSK-3 or Axin can also be 
immunoprecipitated followed by in vitro assay for GSK-3 activity based on its 
ability to phosphorylate added substrates. Interestingly, inducible deletion of Gsk-
3 in mouse gastric epithelium phenocopies Apc deletion in gastric epithelium. 
Within a few days of Gsk-3 or Apc deletion, intestinal-type gastric adenomas 
develop in the antrum, and fundic gland polyps form in the corpus (Radulescu et 
al., 2012). These data suggest loss of GSK-3 activity could be responsible for 
tumorigenesis resulting from APC loss of function.  
Our data suggest mTORC1 activation may contribute to tumorigenesis 
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downstream of Apc mutation. In support of this, the mTORC1 inhibitors 
rapamycin and RAD001 reduce the number of intestinal polyps and extend 
survival of Apcmin mice (Koehl et al., 2010; Metcalfe et al., 2010). RAD001 also 
reduces polyp number and polyp size, and extends survival of ApcΔ716 mice that 
also have a truncating Apc mutation within the mutation cluster region (Fujishita 
et al., 2008).  
β-catenin is also important downstream of Apc. β-catenin knockdown 
reduces the size of resultant tumors when Apc mutant colorectal cancer cells are 
xenografted to mice (Roh et al., 2001; Scholer-Dahirel et al., 2011). β-catenin 
knockdown also reduces adenoma cell proliferation and the number of 
adenomas in Apcmin mice (Foley et al., 2008). These data suggest both mTORC1 
and β-catenin activation contribute to tumorigenesis. Interestingly, constitutive β-
catenin activation in the urothelium synergizes with PTEN loss of function, which 
activates mTORC1, to promote bladder tumorigenesis. This synergism is blocked 
by rapamycin (Ahmad et al., 2011). Future experiments should combine β-
catenin knockdown with mTORC1 inhibition in Apc mutant mice to see if 
combined treatment is more effective than either treatment alone at reducing the 
number and size of adenomas, as well as extending survival. Sphingadiene 
treatment reduces Wnt signaling in Apcmin mice and reduces the number of 
intestinal adenomas, similar to rapamycin. Combining sphingadiene and 
rapamycin treatment has an additive effect of reducing adenoma number (Kumar 
et al., 2012). These data suggest combined Wnt and mTORC1 inhibition is more 
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effective than inhibition of either pathway alone. However, this result should be 
confirmed with more specific and well-established methods of inhibiting Wnt 
signaling (such as β-catenin knockdown).  
Interestingly, Apc mutation may initiate adenoma formation prior to 
activation of Wnt/β-catenin signaling. In humans, nuclear β-catenin is detected in 
less than 10% of sporadic Apc mutant polyps and early adenomas in FAP, but is 
detected much more frequently in later stage carcinomas (Anderson et al., 2002; 
Kobayashi et al., 2000; Phelps et al., 2009). Nuclear β-catenin is also rarely 
observed in microadenomas in a rat model of FAP (Amos-Landgraf et al., 2007). 
Intestinal hyperproliferation in apcmcr/mcr zebrafish also occurs in the absence of 
detectable nuclear β-catenin or expression of a Wnt reporter (Phelps et al., 
2009). These data raise the possibility that Apc mutant intestinal adenomas could 
develop initially in the absence of active β-catenin signaling. Thus it is interesting 
to speculate that mTORC1 activation may have a role in early adenoma 
formation. To test this possibility we could conditionally delete (or truncate) Apc 
in rat intestine and observe the timing of mTORC1 activation compared to 
nuclear β-catenin localization and activation of Wnt target genes. We could then 
inhibit mTORC1 or β-catenin signaling at various times after Apc deletion to 
determine when each pathway is required during tumor development and 
progression. This method would also allow us to distinguish between a 
requirement for mTORC1 or β-catenin signaling in tumor initiation as opposed to 
growth or maintenance of established tumors.  
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4-7. Conclusion 
 
  In conclusion, we identify new roles for APC through its ability to directly 
enhance GSK-3 activity. We find previously unappreciated roles for APC in 
regulating Glycogen Synthase and mTORC1, and our work provides a 
mechanism for APC function in numerous other GSK-3 dependent cellular 
processes and signaling pathways. We also identify new mechanisms for 
regulation of APC and GSK-3 in the Wnt signaling pathway to answer the 
longstanding question of how Wnt signaling reduces GSK-3 activity. Finally, we 
demonstrate that mTORC1 is essential for mediating the effects of oncogenic 
Apc mutation, thus establishing a new model of colorectal cancer pathogenesis.  
 Future work will focus on defining the breadth of GSK-3 substrates 
regulated by APC and exploring the mechanisms of Axin-independent APC/GSK-
3 interaction. Future work will also test the prediction that combined inhibition of 
mTORC1 and Wnt/β-catenin signaling will efficiently block development and 
progression of colorectal tumors.  
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